UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the fiscal year ended December 31, 2003
-----------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to
---------- ---------
Commission file number 0-22245
-------
NEXMED, INC
-----------
(Exact Name of Registrant as Specified in Its Charter)
NEVADA 87-0449967
------ ----------
(State or Other Jurisdiction of Incorporation or (I.R.S. Employer
Organization) Identification No.)
350 CORPORATE BOULEVARD, ROBBINSVILLE, NJ 08691
-----------------------------------------------
(Address of Principal Executive Offices)
(609) 208-9688
--------------
(Registrant's telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Name of Exchange on Which Registered
------------------- ------------------------------------
COMMON STOCK, PAR VALUE $.001 THE NASDAQ NATIONAL MARKET
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. X
---
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Exchange Act Rule 12b-2) Yes X No
-- --- ---
As of March 1, 2004 40,229,686 shares of the common stock, par value
$.001, of the registrant were outstanding and the aggregate market value of the
common stock held by non-affiliates, based upon the last sale price of the
registrant's common stock on June 30, 2003, was approximately $116,788,706.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of our Proxy Statement to be delivered to our stockholders in
connection with the Annual Meeting of Stockholders to be held on May 24, 2004
(the "2004 Proxy Statement") are incorporated by reference into Part III of this
Report.
NEXMED, INC.
INDEX TO ANNUAL REPORT ON FORM 10-K FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION
YEAR ENDED DECEMBER 31, 2003
ITEMS IN FORM 10-K
------------------
Page
----
PART I.
Item 1. BUSINESS......................................................... 1
Item 2. PROPERTIES....................................................... 11
Item 3. LEGAL PROCEEDINGS................................................ 11
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.............. 12
PART II.
Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES................ 12
Item 6. SELECTED FINANCIAL DATA.......................................... 13
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS............................................ 13
Item 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK....... 20
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA...................... 20
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE....................................... 45
Item 9A. CONTROLS AND PROCEDURES ......................................... 45
PART III.
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT............... 45
Item 11. EXECUTIVE COMPENSATION........................................... 46
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.................................... 46
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS................... 46
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES........................... 46
PART IV.
Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.. 46
PART I.
ITEM 1. BUSINESS.
Some of the statements contained in this Report discuss future
expectations, contain projections of results of operations or financial
condition or state other "forward-looking" information. Those statements include
statements regarding the intent, belief or current expectations of the Company
and its management team. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ materially from
those projected in the forward-looking statements. These risks and uncertainties
include but are not limited to, those risks and uncertainties set forth under
the heading "Factors That Could Affect Our Future Results" of Part I of this
Report. In light of the significant risks and uncertainties inherent in the
forward-looking statements included in this Report, the inclusion of such
statements should not be regarded as a representation by us or any other person
that our objectives and plans will be achieved.
GENERAL
NexMed, Inc., (the "Company," which may be referred to as "we," "us,"
or "our") is a pharmaceutical and medical technology company. We develop and
commercialize therapeutic products based on proprietary delivery systems. We are
currently focusing our efforts on new and patented pharmaceutical products based
on a penetration enhancement drug delivery technology known as NexACT(R), which
may enable an active drug to be better absorbed through the skin.
PRODUCTS & TECHNOLOGIES
We have been in existence since 1987. Since 1994, we have positioned
ourselves as a pharmaceutical and medical technology company with a focus on
developing and commercializing therapeutic products based on proprietary
delivery systems. We, together with our subsidiaries, are focusing our efforts
on new and patented pharmaceutical products based on a penetration enhancement
drug delivery technology known as NexACT(R), which may enable an active drug to
be better absorbed through the skin. The NexACT(R) transdermal drug delivery
technology is designed to enhance the absorption of an active drug through the
skin, overcoming the skin's natural barrier properties and enabling high
concentrations of the active drug to rapidly penetrate the desired site of the
skin or extremity. Successful application of the NexACT(R) technology would
improve therapeutic outcomes and reduce dose requirement, dosing frequency, and
systemic side effects that often accompany oral and injectable medications.
We intend to continue our efforts developing transdermal treatments
including cream, gel, patch and tape, based on the application of NexACT(R)
technology to drugs: (1) previously approved by the FDA, (2) with proven
efficacy and safety profiles, (3) with patents expiring or expired and (4) with
proven market track records and potential.
We are focusing our application of the NexACT(R) technology to
Alprox-TD(R) cream for the treatment of male erectile dysfunction. We have
explored the application of the NexACT(R) technology to other drug compounds and
delivery systems, and are in various stages of developing new treatments for
female sexual arousal disorder , nail fungus, premature ejaculation, urinary
incontinence, wound healing, pain and the prevention of nausea and vomiting
associated with post-operative surgical procedures and cancer chemotherapy.
Alprox-TD(R) is an alprostadil-based cream treatment intended for
patients with mild, moderate or severe erectile dysfunction. Our clinical
studies have demonstrated that NexACT(R) enhancers promote the rapid absorption
of alprostadil and improve clinical responses. In December 2002, we completed
our two pivotal Phase 3 studies for Alprox-TD(R), which tested over 1,700
patients at 85 sites throughout the U.S. The two pivotal studies were
randomized, double-blind, placebo-controlled, and designed to confirm the
efficacy and safety of Alprox-TD(R) in patients with varying degrees of erectile
dysfunction. In June 2003 we announced positive results from these two pivotal
Phase 3 studies. The side effects reported were mild to moderate, localized and
transient.
1
We are currently engaged in discussions and contract negotiations with
several pharmaceutical companies regarding possible strategic marketing
partnership(s) for Alprox-TD(R). If partnership arrangements are successfully
completed, the partner(s) will obtain marketing rights for Alprox-TD(R) for
certain markets, in exchange for milestone payments and other future payments to
us. However, in each case consummation of the transaction is subject to the
negotiation of complex contractual relationships, and we may not be able to
negotiate such agreements on a timely basis, if at all, or on terms acceptable
to us.
Prior to filing a new drug application for Alprox-TD(R), we will be
required to initiate a new long-term open-label safety study. We had previously
initiated an open-label study, which was halted in November 2002 due to FDA
concerns about results of our transgenic mice study. The duration of this study
is 12 months. However, we have determined with the FDA that completion of the
open-label study is not a prerequisite for our new drug application submission
provided that the 12-month safety update on 100 patients is filed within four
months after new drug application submission. We are required to have three
hundred patients complete six months of testing in the study at the time of new
drug application submission, and 100 patients must complete the 12-month study
prior to new drug application approval.
In late 2003, we met with the FDA to evaluate our Alprox-TD(R) NDA
package and to discuss possible product improvements. At that time, the FDA
requested that we include a tolerance study of Alprox-TD(R) in female subjects
as part of our new drug application submission. We are about to submit a plan
for a 48-patient study to the FDA for their review and comment. Assuming that
the FDA agrees with our plan, we intend to implement this plan concurrently with
the open label study and complete it prior to the new drug application
submission.
During the same meeting, we proposed to the FDA a new and improved
formulation of Alprox-TD(R), to include in our new drug application filing. The
FDA has permitted us to switch to the new formulation if we conduct two bridging
studies to confirm the efficacy of the new formulation. We intend to conduct
these two studies concurrently with the open-label study and complete them prior
to the new drug application filing. We also proposed to the FDA to conduct a
study of Alprox-TD(R) in men who have failed with oral erectile dysfunction
medication. Industry estimates indicate that a large number of patients who have
tried oral erectile dysfunction medications have discontinued their use due
either to failure to get a satisfactory response or for other reasons. This type
of study is typically considered a Phase 4 or a post approval study. However,
based on the positive response of FDA to this proposal, we are considering early
initiation of the study so that its results can be incorporated into the new
drug application.
The timeframe for us to complete these studies largely depends on our
ability to obtain financing through a partnering agreement for Alprox-TD(R) or
from other sources, and on FDA review. Assuming we begin patient enrollment for
the long-term open-label study in March 2004, we anticipate that we will file
the new drug application in the first half of 2005. However, this timeframe may
change if we encounter any delay in financing, clinical testing or FDA review.
If we are not able to successfully arrange financing through a partnering
agreement or from other sources, we may be required to discontinue the
development of Alprox-TD(R). In addition, it is possible that we may not have
successful clinical results or receive FDA approval on a timely basis, if at
all.
In April 2002, Alprox-TD(R) was launched in Hong Kong under the
Befar(R) trademark. The product, which has been selling in China since October
2001, is manufactured and marketed by a local affiliate of Vergemont
International Limited, our Asian licensee. We receive from our Asian licensee
royalty payments and payments for manufacturing supplies in connection with the
distribution of Befar(R) in China and will receive such payments in other Asian
markets once Befar(R) is approved for marketing in such other markets. The sale
of Befar(R) has been slower than anticipated for several reasons. First , the
switching of distributors by our Asian licensee in China and in Hong Kong during
2003 significantly disrupted sale of the product in the two markets. Secondly,
Befar(R), along with the currently approved oral erectile dysfunction product,
are currently classified in China as controlled substances, and their
distribution is limited to prescription by certain urologists and dispensing
through hospitals. In addition, China has a limited number of patients who can
afford erectile dysfunction treatments. In December 2002 and February 2003, our
Asian licensee entered into licensing agreements for two of our NexACT(R)-based
products, with CJ Pharmaceuticals, one of the five largest pharmaceutical
companies in South
2
Korea. Its parent company, CJ Corporation, is a $7 billion conglomerate in South
Korea. Pursuant to the terms of the agreement, CJ Pharmaceuticals will develop,
file for regulatory approval, market and distribute Befar(R) and Femprox(R) in
South Korea.
We have explored the application of the NexACT(R) technology to other
drug compounds and delivery systems. The furthest advanced of these products is
Femprox(R), which is an alprostadil-based cream product intended for the
treatment of female sexual arousal disorder. We have completed one Phase 2 study
for Femprox(R) and intend to continue with its U.S. clinical development pending
the availability of a partnering agreement. We anticipate that during 2004 we
will file at least one Investigational New Drug application with the FDA for
another NexACT(R)-based product under development and commence Phase 1 clinical
testing of that product in the U.S.
We are also working with various pharmaceutical companies to explore
the introduction of NexACT(R) into their existing drugs as a means of developing
new patient-friendly products and extending patent lifespans. In 2003, we
entered into a series of R&D agreements with Japanese pharmaceutical companies
to develop new treatments based on our NexACT(R) technology.
In November 2003, the Company entered into an agreement with a Japanese
pharmaceutical company whereby NexMed will provide contract development services
for an innovative topical treatment for a form of herpes. The Company received
$100,000 as a signing payment, of which, it has recognized revenue of
approximately $13,000 in 2003 and has deferred approximately $87,000 in revenue
that is expected to be recognized upon completion of the first phase of
development in the first quarter of 2004. Pending the satisfactory completion of
certain milestones, the Company expects to receive additional payments from the
development partner.
In November 2003, the Company entered into an R&D agreement with a
Japanese pharmaceutical company to develop a new local anesthetics gel designed
for pain relief associated with dental procedures, superficial skin surgery and
skin graft harvesting, and needle insertions. Pursuant to the terms of the
agreement, the Company retains the rights to manufacture and commercialize the
new product worldwide except in Japan. The Company recognized revenue of
approximately $5,000 in 2003 and has deferred approximately $41,000 in revenue
that is expected to be recognized upon completion of the first phase of
development in the first quarter of 2004. Pending the satisfactory completion of
certain milestones, the Company expects to receive additional payments from the
development partner.
In October 2003, the Company entered into an R&D agreement with a
Japanese Pharmaceutical company to develop a tape/patch treatment for chronic
pain. Pursuant to the terms of the agreement, the Company retains the rights to
manufacture and commercialize the new product worldwide except in Japan. The
Company recognized revenue of approximately $21,000 in 2003. The Company
completed the first phase of development but the development partner decided to
suspend all remaining development work on this project due to new regulatory
developments in Japan. As such, there will be no additional revenue from the
Japanese pharmaceutical company should the Company continue to develop this
product further.
In August 2003, the Company entered into an R&D agreement with a
Japanese pharmaceutical company to develop NM 20138, a new once-a-day patch
treatment for bronchial asthma, which incorporates an off-patent anti-asthmatic
drug compound and the NexACT(R) technology. Pursuant to the terms of the
agreement, the Company retains the rights to manufacture and commercialize the
new product worldwide except in Japan. The Company recognized revenue of
approximately $21,000 in 2003. The Company completed the first phase of
development but the partner elected not to take the project to the next stage of
development due to proprietary reasons. As such, there will be no additional
revenue from the Japanese pharmaceutical company should the Company continue to
develop this product further.
In August 2002, the Company entered into a research and development
agreement with a Japanese pharmaceutical company. Pursuant to the terms of this
agreement, the Company was to develop a new tape/patch treatment for urinary
dysfunction which incorporates the Japanese partner's proprietary drug compound
with the NexACT(R) technology. Pursuant to the terms of the agreement, the
Company retains the rights to manufacture and commercialize the new product
worldwide except in Japan. The Company recognized revenue of approximately
3
$42,000 and $85,000 in 2003 and 2002 respectively. The Company completed the
first phase of development and the Japanese pharmaceutical company elected not
to take the project to the next stage of development due to proprietary reasons.
As such, there will be no additional revenue from the Japanese pharmaceutical
company should the Company continue to develop this product further.
We anticipate that we will enter into additional R&D agreements during
the next twelve months but we cannot assure you that we will be able to conclude
any arrangement on a timely basis, if at all, or on terms acceptable to us.
SEGMENT AND GEOGRAPHIC AREA INFORMATION
You can find information about our business segment and geographic
areas of business in Note 16 of the Notes to Consolidated Financial Statements.
EMPLOYEES
As of March 1, 2004, we had 48 full time employees, 9 of whom have Ph.D
degrees, 4 of whom are executive management and 31 of whom are engaged in
research and development activities. We also rely on a number of consultants.
None of our employees is represented by a collective bargaining agreement. We
believe that we have a good relationship with our employees.
EXECUTIVE OFFICERS
The Executive Officers of the Company are set forth below.
Name Age* Title
---- ---- -----
Y. Joseph Mo, Ph.D. 56 Chairman of the Board of Directors, President and Chief Executive Officer
James L. Yeager, Ph.D. 57 Director, Senior Vice President, Scientific Affairs
Vivian H. Liu 42 Vice President, Chief Financial Officer and Secretary
Kenneth F. Anderson 57 Vice President, Commercial Development
* As of February 29, 2004
Y. Joseph Mo, Ph.D., is, and has been since 1995, our Chief Executive
Officer and President and Chairman and a member of our board of directors. His
current term as member of our board of directors expires in 2005. Prior to
joining us in 1995, Dr. Mo was President of Sunbofa Group, Inc., a
privately-held investment consulting company. From 1991 to 1994, he was
President of the Chemical Division, and from 1988 to 1994, the Vice President of
Manufacturing and Medicinal Chemistry, of Greenwich Pharmaceuticals, Inc. Prior
to that, he served in various executive positions with several major
pharmaceutical companies, including Johnson & Johnson, Rorer Pharmaceuticals,
and predecessors of Smithkline Beecham. Dr. Mo received his Ph.D. in Industrial
and Physical Pharmacy from Purdue University in 1977.
James L. Yeager, Ph.D., is, and has been since December 1998, a member
of the Board of Directors and, since January 2002, Senior Vice President for
Scientific Affairs. His current term as member of our board of directors expires
in 2005. From June 1996 through December 2001, Dr. Yeager served as the
Company's Vice President of Research and Development and Business Development.
Before joining the Company, Dr. Yeager was Vice President of Research and
Development at Pharmedic Company. From 1979 to 1992, Dr. Yeager held various
positions with Abbott Laboratories and Schiaparelli-Searle. Dr. Yeager received
his Ph.D. in Industrial and Physical Pharmacy from Purdue University in
1978.
4
Vivian H. Liu is, and has been, our Vice President of Corporate Affairs
and Secretary since September 1995 and Chief Financial Officer since January
2004. In 1994, while we were in a transition period, Ms. Liu served as our Chief
Executive Officer. From September 1995 to September 1997, Ms. Liu was our
Treasurer. From 1985 to 1994, she was a business and investment adviser to the
government of Quebec and numerous Canadian companies with respect to product
distribution, technology transfer and investment issues. Ms. Liu received her
MPA in International Finance from the University of Southern California and her
BA from the University of California, Berkeley.
Kenneth F. Anderson is and has been, our Vice President of Commercial
Development since November 2000. Mr. Anderson has extensive experience in the
pharmaceutical industry. From 1997 to September 2000, Mr. Anderson was Senior
Vice President, Director of Strategy and Business Development for Harrison
Wilson & Associates, a consulting and marketing firm specializing in healthcare
products and services. From 1980 to 1997, Mr. Anderson was at Bristol-Myers
Squibb where he served in various management positions, including Senior Manager
for Marketing and Director for Worldwide Business Development. From 1969 to
1979, Mr. Anderson was with Parke-Davis, a division of Warner Lambert. Mr.
Anderson received his BA from Boston University.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements and
other information with the Securities and Exchange Commission, and we have an
internet website address at http://www.nexmed.com. We make available free of
charge on our internet website address our annual report on Form 10-K, quarterly
reports on Form 10-Q, current reports on Form 8-K, and amendments to those
reports filed or furnished pursuant to Sections 13(a) or 15(d) of the Exchange
Act as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the SEC. You may also read and copy any document we file
at the Securities and Exchange Commission's public reference room located at 450
Fifth Street, N.W., Washington, D.C. 20549. Please call the Securities and
Exchange Commission at 1-800-732-0330 for further information on the operation
of such public reference room. You also can request copies of such documents,
upon payment of a duplicating fee, by writing to the Securities and Exchange
Commission at 450 Fifth Street, N.W., Washington, D.C. 20549 or obtain copies of
such documents from the Securities and Exchange Commission's website at
http://www.sec.gov.
FACTORS THAT COULD AFFECT OUR FUTURE RESULTS
RISKS RELATED TO THE COMPANY
WE HAVE A NEED FOR ADDITIONAL FINANCING.
We are currently continuing with the development of Alprox-TD(R), but
have put on hold the development of Femprox(R) and other pipeline products,
pending the availability of additional financing. Our cash position as of March
2, 2004 is approximately $7.5 million, following successful completion of a
private placement in December 2003 of Convertible Notes, yielding net proceeds
to us of approximately $6 million. We have been actively seeking financing from
the sale of equity or issuance of debt from private and public sources as well
as from collaborative licensing and/or marketing arrangements with third
parties, and since December 31, 2002, we have raised approximately $26.1 million
net through the sale of Preferred Stock, the exercise of warrants to purchase
shares of our common stock and the issuance by the Company of notes, Common
Stock and warrants to purchase shares of Common Stock. Our anticipated cash
requirements for Alprox-TD(R) through the new drug application filing in the
first half of 2005, including completion of an open-label study, is expected to
be approximately $20 million. Initiation, but not completion of the open-label
study is a prerequisite for our new drug application submission. There is no
assurance that we will be successful in obtaining financing on acceptable terms,
if at all. If additional financing cannot be obtained on reasonable terms,
future operations may need to be scaled back or discontinued.
5
WE CONTINUE TO INCUR OPERATING LOSSES.
Our current business operations began in 1994 and we have a limited
operating history. We may encounter delays, uncertainties and complications
typically encountered by development stage businesses. We have generated minimal
revenues from the limited sales of Befar(R) in Asia and our existing research
and development agreement with the Japanese partner, and have not marketed or
generated revenues in the U.S. from our products under development. We are not
profitable and have incurred an accumulated deficit of $85,221,535 since our
inception. Our ability to generate revenues and to achieve profitability and
positive cash flow will depend on the successful commercialization of our
products currently under development. However, even if we eventually generate
revenues from sales of our products currently under development, we expect to
incur significant operating losses over the next several years. Our ability to
become profitable will depend, among other things, on our (1) development of our
proposed products, (2) obtaining of regulatory approvals of our proposed
products on a timely basis and (3) success in manufacturing, distributing and
marketing our proposed products.
OUR INDEPENDENT ACCOUNTANTS HAVE DOUBT AS TO OUR ABILITY TO CONTINUE AS A GOING
CONCERN FOR A REASONABLE PERIOD OF TIME.
As a result of our losses to date, expected losses in the future,
limited capital resources and accumulated deficit, our independent auditors have
concluded that there is substantial doubt as to our ability to continue as a
going concern for a reasonable period of time, and have modified their report in
the form of an explanatory paragraph describing the events that have given rise
to this uncertainty. These factors may make it more difficult for us to obtain
additional funding to meet our obligations. Our continuation is based on our
ability to generate or obtain sufficient cash to meet our obligations on a
timely basis and ultimately to attain profitable operations. We anticipate that
we will continue to incur significant losses until successful commercialization
of one or more of our products, and we may never operate profitably in the
future.
WE WILL NEED SIGNIFICANT ADDITIONAL FUNDING TO CONTINUE WITH OUR RESEARCH AND
DEVELOPMENT EFFORTS.
Our research and development expenses for the years ended December 31,
2003, 2002 and 2001, were $8,439,340, $21,615,787 and $12,456,384, respectively.
Since January 1, 1994, when we repositioned ourselves as a medical and
pharmaceutical technology company, we have spent $59,134,688 on research and
development. While our expenses for research and development were significantly
lower in 2003 than in 2002, we expect them to increase significantly in 2004.
Given our current level of cash reserves and low rate of revenue generation, we
will not be able to fully advance the development of our products unless we
raise additional cash through financing from the sale of our securities and/or
through partnering agreements. If we are successful in entering partnering
agreements for our products under development, we will receive milestone
payments, which will offset some of our research and development expenses.
As indicated above, our anticipated cash requirements for Alprox-TD(R)
through the new drug application filing in the first half of 2005, including
completion of an open-label study, will be approximately $20 million.
Initiation, but not completion of the open-label study is a prerequisite for our
New Drug Application filing.
We will also need significant funding to pursue our overall product
development plans. In general, our products under development will require
significant time-consuming and costly research and development, clinical
testing, regulatory approval and significant additional investment prior to
their commercialization. The research and development activities we conduct may
not be successful; our products under development may not prove to be safe and
effective; our clinical development work may not be completed; and the
anticipated products may not be commercially viable or successfully marketed.
Commercial sales of our products cannot begin until we receive final FDA
approval. The earliest time for such final approval of the first product which
may be approved, Alprox-TD(R), is sometime in late 2005. We intend to focus our
current development efforts on the Alprox-TD(R) cream treatment, which is in the
late clinical development stage.
6
WE WILL NEED TO PARTNER TO OBTAIN EFFECTIVE SALES, MARKETING AND DISTRIBUTION.
We currently have no sales force or marketing organization and will
need, but may be unable to attract or afford qualified or experienced marketing
and sales personnel. In addition, we will need to secure a marketing partner who
is able to devote substantial marketing efforts to achieve market acceptance for
our proprietary products under development. The marketing partner will need to
spend significant funds to inform potential customers, including third-party
distributors, of the distinctive characteristics and benefits of our products.
Our operating results and long term success will depend, among other things, on
our ability to establish (1) successful arrangements with domestic and
international distributors and marketing partners and (2) an effective internal
marketing organization. We are currently engaged in discussions and contract
negotiations with several pharmaceutical companies regarding possible strategic
marketing partnership(s) for the Alprox-TD(R) cream. However, in each case
consummation of the transaction is subject to the negotiation of complex
contractual relationships, and we may not be able to negotiate such agreements
on a timely basis, if at all, or on terms acceptable to us.
In Asia, our subsidiary, NexMed International Limited, and our Asian
licensee, Vergemont International Limited, entered into a license agreement in
1999 pursuant to which (1) Vergemont International Limited has an exclusive
right to manufacture and market in Asian Pacific countries, our Alprox-TD(R)
Femprox(R) and three other of our proprietary products under development, and
(2) we receive a royalty on sales and supply, on a cost plus basis, the
NexACT(R) enhancers that are essential in the formulation and production of our
proprietary products. In 2003, we recorded very limited payments from our Asian
licensee for royalties on sales of Befar(R) in China and Hong Kong and for
manufacturing supplies purchased from us.
PRE-CLINICAL AND CLINICAL TRIALS ARE INHERENTLY UNPREDICTABLE. IF WE DO NOT
SUCCESSFULLY CONDUCT THESE TRIALS, WE MAY BE UNABLE TO MARKET OUR PRODUCTS AND
OUR REVENUES MAY DECLINE.
Through pre-clinical studies and clinical trials, we must demonstrate
that our products are safe and effective for their indicated uses. Results from
pre-clinical studies and early clinical trials may not allow us to predict
results in later-stage testing. Our future clinical trials may not demonstrate
the safety and effectiveness of our products or may not result in regulatory
approval to market our products. The failure of the FDA to approve our products
for commercial sales will have a material adverse effect on our prospects.
PATENTS AND INTELLECTUAL PROPERTY RIGHTS ARE IMPORTANT TO US BUT COULD BE
CHALLENGED.
Proprietary protection for our pharmaceutical products is of material
importance to our business in the U.S. and most other countries. We have sought
and will continue to seek proprietary protection for our products to attempt to
prevent others from commercializing equivalent products in substantially less
time and at substantially lower expense. Our success may depend on our ability
to (1) obtain effective patent protection within the U.S. and internationally
for our proprietary technologies and products, (2) defend patents we own, (3)
preserve our trade secrets, and (4) operate without infringing upon the
proprietary rights of others.
We have nine U.S. patents either acquired or received out of a series
of patent applications that we have filed in connection with our NexACT(R)
technology and our NexACT(R) -based products under development, such as
Alprox-TD(R), Femprox(R), and our non-steroidal anti-inflammatory cream. To
further strengthen our global patent position with respect to our proprietary
products under development, and to expand the patent protection to other
markets, we have filed under the Patent Cooperation Treaty, corresponding
international applications for our issued U.S. patents and pending U.S. patent
applications.
7
The following table identifies our nine U.S. patents issued for
NexACT(R) technology and/or our NexACT-based products under development, and the
year of expiration for each patent:
Patent Name Expiration Date
- ----------- ---------------
Biodegradable Absorption Enhancers 2008
Biodegradable Absorption Enhancers 2009
Compositions and Methods for Amelioration of Human Female Sexual Dysfunction 2017
Topical Compositions for PGE1 Delivery 2017
Topical Compositions for Non-Steroidal Anti-Inflammatory Drug Delivery 2017
Medicament Dispenser 2019
Crystalline Salts of dodecyl 2-(N, N-Dimethylamino) 2019
Topical Compositions Containing Prostaglandin E1 2019
Prostaglandin Composition and Methods of Treatment of Male Erectile Dysfunction 2020
While we have obtained patents and have several patent applications
pending, the extent of effective patent protection in the U.S. and other
countries is highly uncertain and involves complex legal and factual questions.
No consistent policy addresses the breadth of claims allowed in or the degree of
protection afforded under patents of medical and pharmaceutical companies.
Patents we currently own or may obtain might not be sufficiently broad to
protect us against competitors with similar technology. Any of our patents could
be invalidated or circumvented.
There have been patents issued to other companies such as Vivus, Inc.
and MacroChem Corporation on the use of alprostadil for the treatment of male or
female sexual dysfunction. While we believe that our patents would prevail in
any potential litigation, we can provide no assurance that the holders of these
competing patents will not commence a lawsuit against us or that we would
prevail in any such lawsuit. Litigation could result in substantial cost to and
diversion of effort by us, which may harm our business. In addition, our efforts
to protect or defend our proprietary rights may not be successful or, even if
successful, may result in substantial cost to us.
WE DEPEND UPON THIRD PARTY MANUFACTURERS FOR OUR CHEMICAL MANUFACTURING
SUPPLIES.
In 2002, we completed the construction of a 31,500 square foot
industrial facility, located in East Windsor, New Jersey, which we are in the
process of developing and validating as a manufacturing facility designed to
meet the Good Manufacturing Practice (GMP) standards as required by the FDA. We
anticipate that our manufacturing facility will have the capacity to meet our
anticipated needs for full-scale commercial production. Initially, we are
utilizing the facility to manufacture Alprox-TD(R) and other NexACT(R)-based
products under development for continuing clinical testing purposes. We are also
validating the facility for GMP compliance, which is a requirement for our new
drug application filing with the FDA. If we do not successfully pass the
Pre-Approved Inspection conducted by the FDA, our new drug application filing
will be delayed.
We depend on third party chemical manufacturers for alprostadil, the
active drugs in Alprox-TD(R) and in other NexACT-based products under
development, and for the supply of our NexACT(R) enhancers that are essential in
the formulation and production of our products, on a timely basis and at
satisfactory quality levels. If our validated third party chemical manufacturers
fail to produce quality products on time and in sufficient qualities, our
results would suffer, as we would encounter costs and delays in revalidating new
third party suppliers.
WE FACE SEVERE COMPETITION.
We are engaged in a highly competitive industry. We expect increased
competition from numerous existing companies, including large international
enterprises, and others entering the industry. Most of these companies have
greater research and development, manufacturing, marketing, financial,
technological, personnel and managerial resources. Acquisitions of competing
companies by large pharmaceutical or healthcare companies could further enhance
such competitors' financial, marketing and other resources. Competitors may
complete clinical trials, obtain regulatory approvals and commence commercial
sales of their products before we could enjoy a significant competitive
advantage. In addition, products developed by our competitors may be more
effective than our products.
Certain treatments for erectile dysfunction, such as needle injection
therapy, vacuum constriction devices, penile implants, transurethral absorption
and oral medications, currently exist, have been approved for sale in certain
markets and are being improved. Currently known products for the treatment of
erectile dysfunctiondeveloped or under
8
development by our competitors include the following: (1) Caverject(R), Pfizer's
needle injection therapy; (2) Viagra(R), Pfizer, Inc.'s oral product to treat
ED; (3) Cialis(R), an oral formulation marketed in the U.S. through a joint
venture between ICOS and Eli Lilly & Co; (4) Levitra(R), an oral medication
marketed through a collaborative effort of Bayer AG and GlaxoSmithKline, Inc and
(5) Muse(R), Vivus, Inc.'s device for intra-urethral delivery of a suppository
containing alprostadil. In addition, the following products are currently under
development: (1) Topiglan(R), a topical treatment containing alprostadil based
on a proprietary drug delivery system under development by MacroChem
Corporation; (2) PT-141, an intra-nasal treatment containing a new peptide under
development by Palatin Technologies; (3) an intranasal apomorphine treatment
under development by Nastech.
WE ARE THE SUBJECT OF SEVERAL LAWSUITS AND MAY BE SUBJECT TO POTENTIAL PRODUCT
LIABILITY AND OTHER CLAIMS, CREATING RISK AND EXPENSE.
We have been the subject of a number of lawsuits. On March 22, 2003,
five former employees filed a lawsuit in the Superior Court of New Jersey
against the Company, Y. Joseph Mo, and Administaff (the co-employer who until
December 31, 2003, provided the Company's benefits), claiming their termination
at the time of the November 2002 lay-off was due to age discrimination and
seeking unspecified damages. This complaint is covered by a labor insurance
policy the Company maintained through Administaff and the insurance company has
appointed counsel.
Another lawsuit was filed with the Superior Court of New Jersey on
April 1, 2003 by one of the above five employees against the Company for an
unspecified bonus amount that he believes he should have received upon
completion of the construction of the Company's East Windsor facility. The
Company has engaged counsel to defend its position.
On December 29, 2003, a consultant previously engaged by the Company
filed a suit in the Superior Court of New Jersey, Chancery Division: Mercer
County, which subsequently was removed to the United States District Court for
the District of New Jersey, alleging a breach by the Company of a consulting
agreement entered into with that consultant in January 2003. The plaintiff
alleged that the Company failed to issue certain warrants provided for under
that agreement, which the Company terminated in April 2003. The complaint did
not specify any particular amount of monetary risk and expense damages. The
Company has engaged counsel to defend its position.
The Company intends to defend itself vigorously against the above
mentioned claims and believes it has valid defenses; however, each of the cases
is still in the preliminary stages and the likely outcomes can not be
predicted, nor can a reasonable estimate of the amount of loss, if any, be made.
We are also exposed to potential product liability risks inherent in
the development, testing, manufacturing, marketing and sale of human therapeutic
products. Product liability insurance for the pharmaceutical industry is
extremely expensive, difficult to obtain and may not be available on acceptable
terms, if at all. We currently have liability insurance to cover claims related
to our products that may arise from clinical trials, with coverage of $1 million
for any one claim and $3 million in total, but we do not maintain product
liability insurance and we may need to acquire such insurance coverage prior to
the commercial introduction of our products. If we obtain such coverage, we have
no guarantee that the coverage limits of such insurance policies will be
adequate. A successful claim against us if we are uninsured, or which is in
excess of our insurance coverage, if any, could have a material adverse effect
upon us and on our financial condition.
INDUSTRY RISKS
WE ARE SUBJECT TO NUMEROUS AND COMPLEX GOVERNMENT REGULATIONS WHICH COULD RESULT
IN DELAY AND EXPENSE.
Governmental authorities in the U.S. and other countries heavily
regulate the testing, manufacture, labeling, distribution, advertising and
marketing of our proposed products. None of our proprietary products under
development has been approved for marketing in the U.S. Before we market any
products we develop, we must obtain FDA and comparable foreign agency approval
through an extensive clinical study and approval process.
9
The studies involved in the approval process are conducted in three
phases. In Phase 1 studies, researchers assess safety or the most common acute
adverse effects of a drug and examine the size of doses that patients can take
safely without a high incidence of side effects. Generally, 20 to 100 healthy
volunteers or patients are studied in the Phase 1 study for a period of several
months. In Phase 2 studies, researchers determine the drug's efficacy with
short-term safety by administering the drug to subjects who have the condition
the drug is intended to treat, assess whether the drug favorably affects the
condition, and begin to identify the correct dosage level. Up to several hundred
subjects may be studied in the Phase 2 study for approximately 6 to 12 months,
depending on the type of product tested. In Phase 3 studies, researchers further
assess efficacy and safety of the drug. Several hundred to thousands of patients
may be studied during the Phase 3 studies for a period of from 12 months to
several years. Upon completion of Phase 3 studies, a new drug application is
submitted to the FDA or foreign governmental regulatory authority for review and
approval.
Our failure to obtain requisite governmental approvals timely or at all
would delay or preclude us from licensing or marketing our products or limit the
commercial use of our products, which could adversely affect our business,
financial condition and results of operations.
Because we intend to sell and market our products outside the U.S., we
will be subject to foreign regulatory requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursements. These
requirements vary widely from country to country. Our failure to meet each
foreign country's requirements could delay the introduction of our proposed
products in the respective foreign country and limit our revenues from sales of
our proposed products in foreign markets.
Successful commercialization of our products may depend on the
availability of reimbursement to the consumer from third-party healthcare
payers, such as government and private insurance plans. Even if we succeed in
bringing one or more products to market, reimbursement to consumers may not be
available or sufficient to allow us to realize an appropriate return on our
investment in product development or to sell our products on a competitive
basis. In addition, in certain foreign markets, pricing or profitability of
prescription pharmaceuticals is subject to governmental controls. In the U.S.,
federal and state agencies have proposed similar governmental control and the
U.S. Congress has recently considered legislative and regulatory reforms that
may affect companies engaged in the healthcare industry. Pricing constraints on
our products in foreign markets and possibly in the U.S. could adversely affect
our business and limit our revenues.
WE ARE VULNERABLE TO VOLATILE MARKET CONDITIONS.
The market prices for securities of biopharmaceutical and biotechnology
companies, including ours, have been highly volatile. The market has from time
to time experienced significant price and volume fluctuations that are unrelated
to the operating performance of particular companies. In addition, future
announcements, such as the results of testing and clinical trials, the status of
our relationships with third-party collaborators, technological innovations or
new therapeutic products, governmental regulation, developments in patent or
other proprietary rights, litigation or public concern as to the safety of
products developed by us or others and general market conditions, concerning us,
our competitors or other biopharmaceutical companies, may have a significant
effect on the market price of our common stock.
RISKS RELATED TO OWNING OUR COMMON STOCK
WE DO NOT EXPECT TO PAY DIVIDENDS ON OUR COMMON STOCK IN THE FORESEEABLE FUTURE.
Although our shareholders may receive dividends if, as and when
declared by our board of directors, we do not intend to pay dividends on our
Common Stock in the foreseeable future. Therefore, you should not purchase our
Common Stock if you need immediate or future income by way of dividends from
your investment.
10
WE MAY ISSUE ADDITIONAL SHARES OF OUR CAPITAL STOCK THAT COULD DILUTE THE VALUE
OF YOUR SHARES OF COMMON STOCK.
We are authorized to issue 90,000,000 shares of our capital stock,
consisting of 80,000,000 shares of our Common Stock and 10,000,000 shares of our
preferred stock of which 1,000,000 is designated as Series A Junior
Participating Preferred Stock. As of December 31, 2003, 40,123,127 shares of our
Common Stock were issued and outstanding and 13,609,955 shares of our Common
Stock were issuable upon the exercise of options, warrants, or other convertible
securities. There were no shares of Preferred Stock outstanding at December 31,
2003. In light of our need for additional financing, we may issue authorized and
unissued shares of Common Stock at below current market prices or additional
convertible securities that could dilute the earnings per share and book value
of your shares of our Common Stock.
In addition to provisions providing for proportionate adjustments in
the event of stock splits, stock dividends, reverse stock splits and similar
events, certain warrants provide (with certain exceptions) for an adjustment of
the exercise price if we issue shares of common stock at prices lower than the
exercise price or the then prevailing market price. This means that if we need
to raise equity financing at a time when the market price for our common stock
is lower than the exercise price, or if we need to provide a new equity investor
with a discount from the then prevailing market price, the exercise price will
be reduced and the dilution to shareholders increased.
ITEM 2. PROPERTIES.
We currently have our principal executive offices and laboratories in
Robbinsville, NJ. We lease approximately 24,000 square feet of space for $25,000
per month pursuant to a lease which expires in February 2006. We also lease
approximately 5,000 square feet of laboratory space in Monmouth Junction, NJ for
$12,035 per month pursuant to a lease which expires in April 2006.
We own our 31,500 square foot manufacturing facility in East Windsor,
New Jersey. We purchased the facility for $2.2 million and have invested
approximately $7.2 million for construction, equipment and FDA Good
manufacturing practices ("GMP") development.
NexMed International Limited subleases 1,000 square feet of office
space in Hong Kong for $3,000 per month pursuant to a month-to-month
arrangement.
ITEM 3. LEGAL PROCEEDINGS.
On March 22, 2003, five former employees filed a lawsuit in the
Superior Court of New Jersey against the Company, Y. Joseph Mo, and Administaff
(the co-employer who until December 31, 2003, provided the Company's benefits),
claiming their termination at the time of the November 2002 lay-off was due to
age discrimination and seeking unspecified damages. This complaint is covered by
a labor insurance policy the Company maintains through Administaff and the
insurance company has appointed counsel.
Another lawsuit was filed with the Superior Court of New Jersey on
April 1, 2003 by one of the above five employees against the Company for an
unspecified bonus amount that he believes he should have received upon
completion of the construction of the Company's East Windsor facility. The
Company has engaged counsel to defend its position.
On December 29, 2003, a consultant previously engaged by the Company
filed a suit in the Superior Court of New Jersey, Chancery Division: Mercer
County, which subsequently was removed to the United States District Court for
the District of New Jersey, alleging a breach by the Company of a consulting
agreement entered into with that
11
consultant in January 2003. The plaintiff alleged that the Company failed to
issue certain warrants provided for under that agreement, which the Company
terminated in April 2003. The complaint did not specify any particular amount of
monetary risk and expense damages. The Company has engaged counsel to defend its
position.
The Company intends to defend itself vigorously against the above
mentioned claims and believes it has valid defenses; however, each of the cases
is still in the preliminary stages and the likely outcomes can not be
predicted, nor can a reasonable estimate of the amount of loss, if any, be made.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
There was no submission of matters to a vote of security holders.
PART II.
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES.
Our Common Stock is traded on the NASDAQ National Market System (the
"NASDAQ") under the symbol "NEXM."
The following table sets forth the range of the high and low sales
prices as reported by the NASDAQ for the period from January 1, 2002 to December
31, 2003.
Price of Common Stock ($)
-------------------------
High Low
---- ---
Fiscal Year Ended December 31, 2002
-----------------------------------
First Quarter 5.150 2.100
Second Quarter 5.250 2.300
Third Quarter 2.730 1.540
Fourth Quarter 1.990 0.350
Fiscal Year Ended December 31, 2003
-----------------------------------
First Quarter 2.200 0.750
Second Quarter 5.250 1.090
Third Quarter 4.830 2.560
Fourth Quarter 5.650 3.350
On March 1, 2004, the last reported sales price for our Common Stock on
the NASDAQ was $3.38 per share, and we had 224 holders of record of our Common
Stock.
DIVIDENDS
We have never paid cash dividends on our Common Stock and do not have
any plans to pay cash dividends in the foreseeable future. Our board of
directors anticipates that any earnings that might be available to pay dividends
will be retained to finance our business.
12
RECENT SALES OF UNREGISTERED SECURITIES
On December 12, 2003, the Company issued convertible notes (the "2003
Notes") with a face value of $6 million. The 2003 Notes are payable on May 31,
2007 and are collateralized by the Company's manufacturing facility in East
Windsor, New Jersey. The Notes are initially convertible into shares of the
Company's common stock at a conversion price equal to $6.50 per share (923,077
shares). The conversion price will be adjusted on June 14, 2004 to the volume
weighted average price of the Company's stock over the six month period
beginning December 15, 2003 and ending on June 14, 2004 but will be no greater
than $6.50 and no less than $5.00. Interest accretes on the Notes on a
semi-annual basis at a rate of 5% per annum, and the Company may pay such
amounts in cash or by effecting the automatic conversion of such amount into the
Company's common stock at a 10% discount to the then average market prices. The
Notes were issued pursuant to an exemption provided by Section 4(2) of the
Securities Act of 1933. We received $6 million in gross proceeds, which have
been and are being used to fund general corporate overhead expenses and ongoing
U.S. clinical studies.
ITEM 6. SELECTED FINANCIAL DATA.
The following selected financial information is qualified by reference
to, and should be read in conjunction with, the Company's consolidated financial
statements and the notes thereto, and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" contained elsewhere herein.
INCOME STATEMENT DATA For the years ended December 31,
- ---------------------
2003 2002 2001 2000 1999
Revenue
Product sales and royalties $6,206 $63,417 $68,089 0 $1,491,746*
Research and development fees $104,537 $84,611 0 0 0
Net Loss $(17,233,566) $(27,641,519) $(16,174,861) $(8,720,553) $(2,490,600)
Basic and Diluted Loss per Share $(0.60) $(1.03) $(0.63) $(0.40) $(0.18)
Weighted Average Common Shares
Outstanding Used for Basic and Diluted
Loss per Share 33,649,774 26,937,200 25,486,465 21,868,267 13,724,052
BALANCE SHEET DATA December 31, December 31, December 31, December 31, December 31
- ------------------
2003 2002 2001 2000 1999
Total Assets $23,133,679 $14,140,127 $27,314,713 $39,989,682 $7,633,333
Total Long Term Liabilities $7,335,877 $5,782,518 $724,577 $0 $0
Stockholders' Equity $12,723,408 $3,223,492 $24,107,865 $38,744,175 $6,909,739
*Represents revenues from a joint-venture manufacturing facility in
China which NexMed sold in 1999.
We do not have any off-balance sheet arrangements.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
GENERAL
We are focusing our application of the NexACT(R) technology to
Alprox-TD(R) cream for the treatment of male erectile dysfunction. We have
explored the application of the NexACT(R) technology to other drug compounds and
delivery systems, and are in various stages of developing new treatments for
female sexual arousal disorder, nail fungus, premature ejaculation, urinary
incontinence, wound healing, and the prevention of nausea and vomiting
associated with post-operative surgical procedures and cancer chemotherapy.
13
We intend to (1) pursue our research, development, and marketing
activities and capabilities, both domestically and internationally, with regard
to our proprietary pharmaceutical products and (2) execute a business strategy
with the goal of achieving a level of development sufficient to enable us to
attract potential strategic partners with resources sufficient to further
develop and market our proprietary products.
LIQUIDITY AND CAPITAL RESOURCES
We have experienced net losses and negative cash flow from operations
each year since our inception. Through December 31, 2003, we had an accumulated
deficit of $85,221,535. Our operations have principally been financed through
private placements of equity securities and debt financing. Funds raised in past
periods should not be considered an indication of additional funds to be raised
in any future periods.
As a result of our losses to date, expected losses in the future,
limited capital resources and accumulated deficit, our independent accountants
have concluded that there is substantial doubt as to our ability to continue as
a going concern for a reasonable period of time, and have modified their report
in the form of an explanatory paragraph describing the events that have given
rise to this uncertainty. These factors may make it more difficult for us to
obtain additional funding to meet our obligations. Our continuation is based on
our ability to generate or obtain sufficient cash to meet our obligations on a
timely basis and ultimately to attain profitable operations. We anticipate that
we will continue to incur significant losses until successful commercialization
of one or more of our products. There can be no assurance that we can be
operated profitably in the future.
On April 22, 2003, we closed a private placement of our securities and
raised $8 million in gross proceeds. We sold 800 shares of newly issued
convertible preferred stock, with each preferred share initially convertible
into approximately 6,375 shares of the Company's common stock (or an aggregate
of 5,100,089 shares of common stock). Each preferred share had a purchase price
of $10,000 and included a warrant to purchase approximately 5,499 shares of our
common stock at a price of $1.43 per share. On August 1, 2003, we issued a
notice of mandatory conversion to the holders of the preferred stock, as a
result of which all of the outstanding shares of preferred stock were
automatically converted into 5,100,089 shares of common stock. Thus, as of
September 30 2003, no shares of series B preferred stock remained outstanding.
On July 2, 2003, we closed a private placement of our common stock at
$3.60 per share and received $10.5 million in gross proceeds. Pursuant to the
placement agreement, we issued a total of 2,916,669 shares of common stock and
four-year warrants to purchase 1,020,832 shares of our common stock at $5.04 per
share to twelve accredited investors. One third of the warrants will be callable
by us if the market price of our common stock closes above $10.00 for seven
consecutive trading days.
On December 12, 2003, the Company issued convertible notes (the
"Notes") with a face value of $6 million. The Notes are payable on May 31, 2007
and are collateralized by the Company's manufacturing facility in East Windsor,
New Jersey. The Notes are initially convertible into shares of the Company's
common stock at a conversion price initially equal to $6.50 per share (923,077
shares). The conversion price will be adjusted on June 14, 2004 to the volume
weighted average price of the Company's stock over the six month period
beginning December 15, 2003 and ending on June 14, 2004 but will be no greater
than $6.50 and no less than $5.00. Interest accretes on the Note on a
semi-annual basis at a rate of 5% per annum, and the Company may pay such
amounts in cash or by effecting the automatic conversion of such amount into the
Company's common stock at a 10% discount to the then average market prices.
At December 31, 2003, we recorded significantly more non-cash interest
expense charges from convertible notes, including the write-off of the discount
attributable to the $5 million convertible notes converted to common stock in
2003.
14
At December 31, 2003, we had $1,482,426 in prepaid expenses and other
assets primarily as a result the initial deposits made to an independent
clinical research organization for the planned clinical studies for
Alprox-TD(R).
At December 31, 2003, we had $1,273,303 in payroll related liabilities
as compared to $354,992 at December 31, 2002. The increase is attributable to
2003 bonuses of $1,074,400 which were accrued in 2003 and which we plan to pay
in 2004.
A significant portion of our accounts payable and accrued expenses at
December 2002 were incurred as a result of the Phase 3 trials for Alprox-TD(R)
which were completed in December 2002. In 2003, we paid all of these accounts
payable and accrued expenses upon completing the financing transactions
discussed above.
At December 31, 2003, we had cash and cash equivalents, certificates of
deposit and investments in marketable securities of approximately $10.98 million
as compared to $1.57 million at December 31, 2002. To date, we have spent
approximately $63.4 million on the Alprox-TD(R) development program, and
anticipate that we will spend approximately an additional $20 million to
complete the clinical program and file the new drug application for
Alprox-TD(R).
We have spent approximately $9.4 million in total for the land,
building, manufacturing and lab equipment, and GMP development as related to our
East Windsor manufacturing facility and estimate that an additional $2 million,
approximately, will be spent prior to the FDA pre-approval inspection for the
facility. We intend to initiate additional clinical studies for Femprox(R) and
other NexACT(R)-based products, pending the availability of financing.
The timeframe for us to complete the planned clinical studies for
Alprox-TD(R) largely depends on our ability to obtain financing through a
partnering agreement for Alprox-TD(R) or from other sources, and on the FDA
review process. Assuming we begin patient enrollment for the long-term
open-label safety study during March 2004, we anticipate that we will file the
new drug application in first half of 2005. However, this timeframe may change
if we encounter any delay in financing, clinical testing or FDA review. In
addition, it is possible that we may not have successful clinical results or
receive FDA approval on a timely basis, if at all.
We lease office space and research facilities under operating lease
agreements expiring through 2005. We also lease equipment from GE Capital under
capital leases expiring through 2006 (Note 7 of the Financial Statements). The
following table summarizes our contractual obligations and the periods in which
payments are due as of December 31. 2003:
LESS THAN 1 - 3 3 - 5 MORE THAN
CONTRACTUAL OBLIGATIONS TOTAL 1 YEAR YEARS YEARS 5 YEARS
----- ------ ----- ----- -------
Long-term debt * $6,000,000 $0 $0 $6,000,000 $0
Capital lease obligations 1,949,365 1,017,450 931,915 0 0
Operating leases 1,049,211 476,910 572,301 0 0
Purchase obligations ** 11,652,090 7,803,060 3,849,030 0 0
Other long-term liabilities*** 2,625,000 0 0 0 2,625,000
-------------------------------------------------------------------------------
Total $23,275,666 $9,297,420 $5,353,246 $6,000,000 $2,625,000
* Long-term debt consists of two notes that are convertible to common stock at
the option of the noteholders.
** Purchase obligations consists of clinical research agreements that can be
cancelled at any time with thirty days notice. The penalty for our
cancellation of the agreements is 10% of the oustanding contract amount at
the time of cancellation.
*** Represents the fully vested payments to be made according to a deferred
compensation agreement. The partially vested present value of $458,000 of
this obligation is reflected on our balance sheet in other long term
liabilities.
In February 2001, we entered into a financial arrangement with GE
Capital Corporation for a line of credit, which provided for the financing of up
to $5 million of equipment (i) for our new East Windsor, NJ manufacturing
facility and (ii) for our expanded corporate and laboratory facilities in
Robbinsville, NJ. Equipment financed through this facility was in the form of a
42-month capital lease. As of December 31, 2002, we had financed $1,113,459 of
equipment purchases under the GE credit line. The $5 million credit line expired
in March 2002, and as of December
15
31, 2003, there was an outstanding balance due GE of $407,494 under this
facility. This balance is payable in monthly installments through various dates
in 2004 and is reflected in the above table under capital lease obligations.
In January 2002, GE approved a new credit line, which provided for the
financing of up to $3 million of equipment and expired on December 31, 2002.
During 2002, the Company accessed $1,111,427 of the credit line. As of December
31, 2003, there was an outstanding balance due GE of $694,718 under the January
2002 facility. Balances due are payable in 42 monthly installments from the date
of take-down and is reflected in the above table under capital lease
obligations. The $3 million credit line expired on December 31, 2002.
In July 2003, GE approved a new credit line, which expires in July 2004
and provides for the financing of up to $1.85 million of equipment. During 2003,
the Company accessed $738,731 of the credit line. As of December 31, 2003, there
was an outstanding balance due GE of $674,526 under the July 2003 facility,
payable in 36 monthly installments from the date of take-down and is reflected
in the above table under capital lease obligations.
CRITICAL ACCOUNTING ESTIMATES
Our discussion and analysis of our financial condition and results of
operations is based upon our consolidated financial statements, which have been
prepared in accordance with accounting principles generally accepted in the
United States of America. Note 2 in the Notes to the Condensed Consolidated
Financial Statements, includes a summary of the significant accounting policies
and methods used in the preparation of our Consolidated Financial Statements.
The preparation of these financial statements requires our management to make
estimates and assumptions that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. Our accounting policies affect our more significant judgments
and estimates used in the preparation of its financial statements. Actual
results could differ from these estimates. The following is a brief description
of the more significant accounting policies and related estimate methods that we
follow:
Income Taxes--In preparing our financial statements, we make estimates
of our current tax exposure and temporary differences resulting from timing
differences for reporting items for book and tax purposes. We recognize deferred
taxes by the asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred income taxes are recognized for
differences between the financial statement and tax bases of assets and
liabilities at enacted statutory tax rates in effect for the years in which the
differences are expected to reverse. The effect on deferred taxes of a change in
tax rates is recognized in income in the period that includes the enactment
date. In addition, valuation allowances are established when necessary to reduce
deferred tax assets to the amounts expected to be realized.
Critical Estimate: In consideration of our accumulated losses and lack
of historical ability to generate taxable income to utilize our deferred tax
assets, we have estimated that we will not be able to realize any benefit from
our temporary differences and have recorded a full valuation allowance. If we
become profitable in the future at levels which cause management to conclude
that it is more likely than not that we will realize all or a portion of the net
operating loss carry-forward, we would immediately record the estimated net
realized value of the deferred tax asset at that time and would then provide for
income taxes at a rate equal to our combined federal and state effective rates,
which would be approximately 40% under current tax laws. Subsequent revisions to
the estimated net realizable value of the deferred tax asset could cause our
provision for income taxes to vary significantly from period to period.
Long-lived assets--We review for the impairment of long-lived assets
whenever events or circumstances indicate that the carrying amount of an asset
may not be recoverable. An impairment loss would be recognized when estimated
undiscounted future cash flows expected to result from the use of the asset and
its eventual disposition are less than its carrying amount. If such assets are
considered impaired, the amount of the impairment loss recognized is measured as
the amount by which the carrying value of the asset exceeds the fair value of
the asset, fair value being determined based upon discounted cash flows or
appraised values, depending on the nature of the asset. We have not identified
any such impairment losses.
16
Critical Estimate: Estimated undiscounted future cash flows are based
on sales projections for our products under development for which the long-lived
assets are used. In 2003, we performed a review for impairment of our
manufacturing facility based on projections of sales of our product candidates,
for which the facility is anticipated to be ultimately utilized. Overestimating
the future cash flows resulting from the commercialization of Alprox TD(R) may
lead to overstating the carrying value of the manufacturing facility by not
identifying an impairment loss.
Revenue recognition -- Revenues from product sales are recognized upon
delivery of products to customers, less allowances for returns and discounts.
Royalty revenue is recognized upon the sale of the related products, provided
the royalty amounts are fixed or determinable and the amounts are considered
collectible. Revenues earned under research and development contracts are
recognized in accordance with the cost-to-cost method outlined in Staff
Accounting Bulletin No. 101 whereby the extent of progress toward completion is
measured on the cost-to-cost basis; however, revenue recognized at any point
will not exceed the cash received. If the current estimates of total contract
revenue and contract cost indicate a loss, a provision for the entire loss on
the contract would be made. All costs related to these agreements are expensed
as incurred and classified within "Research and development" expenses in the
Condensed Consolidated Statement of Operations and Comprehensive Income.
Critical Estimate: In calculating the progress made toward completion
of a research contract, we must compare costs incurred to date to the total
estimated cost of the project. We estimate the cost of any given project based
on our past experience in product development as well as the past experience of
our research staff in their areas of expertise. Underestimating the total cost
of a research contract may cause us to accelerate the revenue recognized under
such contract. Conversely, overestimating the cost may cause us to delay revenue
recognized.
Research and development -- Research and development expenses include
costs directly attributable to the conduct of our research and development,
including salaries, payroll taxes, employee benefits, materials, supplies,
depreciation on and maintenance of research equipment, costs related to research
and development fee agreements, the cost of services provided by outside
contractors, including services related to our clinical trials, clinical trial
expenses, the full cost of manufacturing drugs for use in research, pre-clinical
and clinical development, and the allocable portion of facility costs.
COMPARISON OF RESULTS OF OPERATIONS BETWEEN THE YEARS ENDED DECEMBER 31, 2003
AND 2002.
Revenues. We recorded revenues of $110,743 during the twelve months of
operations in 2003 as compared to $148,028 during the same period in 2002. The
2003 revenues consisted of $6,206 in royalties on sales received from our Asian
licensee and $104,537 of revenue recognized on our research and development
agreements with Japanese pharmaceutical companies. During 2003, we received an
additional $128,708 from research and development agreements with Japanese
pharmaceutical companies, which we expect to recognize as revenues in 2004 when
we have completed the first phase of development. The sale of Befar(R) in Asia
has been slower than anticipated due to several reasons. Firstly, the changing
of distributors by our Asian licensee in China and in Hong Kong during 2003
significantly disrupted sale of the product in the two markets. Secondly,
Befar(R), along with the currently approved oral erectile dysfunction product,
are currently classified in China as controlled substances, and their
distribution is limited to prescription by certain urologists and dispensing
through hospitals. In addition, China has a limited number of patients who can
afford erectile dysfunction treatments.
Cost of Products Sold. Our cost of products sold was nil and $27,030 in
2003 and 2002, respectively and is attributable to our cost for the
manufacturing supplies sold to our Asian licensee for the production of Befar(R)
in China. Our Asian licensee had a sufficient inventory of the manufacturing
supplies during 2003.
Research and Development Expenses. Our research and development
expenses for 2003 and 2002 were $8,439,340 and $21,615,787, respectively.
Research and development expenses attributable to Alprox-TD(R) and Femprox(R)
for 2003 were $2,885,020 and $35,699, respectively with the balance attributable
to NexACT(R) technology based products and indirect overhead related to research
and development, as compared to approximately $15,835,000 and $642,000,
respectively in 2002. The significant decrease is attributable to the completion
of the costly Phase 3
17
trials for Alprox-TD(R) in December 2002 and a significant reduction in expenses
and non-essential personnel under our cash conservation program implemented in
November 2002. The significant decrease in research and development expenses was
partially offset by an expense of $418,933 in 2003 for bonuses to be paid in
2004 to employees. Research and development expenses include all costs
associated with our research and development agreements. We anticipate that
total research and development spending in 2004 will increase significantly with
the completion of the remaining clinical studies which will cost approximately
$20 million and the anticipated filing of the new drug application for Alprox-TD
in the first half 2005; the increase in efforts and resources on the application
of the NexACT(R) technology to other drug compounds and delivery systems for the
development of new products; and the filing of Investigational New Drug
applications for some of the NexACT(R)-based products under development which
would include the initiation of Phase 1 and 2 clinical studies in the U.S.
Selling, General and Administrative Expenses. Our selling, general and
administrative expenses were $5,900,569 in 2003 as compared to $6,065,347 during
2002. The modest decrease is primarily attributable to the significant reduction
in expenses and non-essential personnel under our cash conservation program
implemented in November 2002 which is offset by an expense of $655,467 in 2003
for bonuses to be paid in 2004 to employees of which approximately $400,000 will
be paid in the Company's common stock. We anticipate that SG&A expenses will
increase significantly in 2004 with the escalation in development activities.
Other income (expense). Other income (expense) was ($152,867) in 2003
as compared to ($81,008) in 2002. The increase is attributable to the loss on
the disposition of property and equipment of $114,542. In 2003, we sold some lab
equipment that was no longer in use in order to generate some additional cash
inflow.
Interest Expense. We recognized $3,159,338 in interest expense during
2003 as compared to $384,286 during 2002. The significant increase in interest
expense is a result of an increase in interest expense charges from convertible
notes, including the write-off of the discount attributable to the $5 million
convertible notes converted to common stock in 2003, and increased borrowings
under our GE Capital facility.
Net Loss. The net loss was $17,233,566 for 2003, as compared to a loss
of $27,641,519 for 2002. The significant decrease in net loss is primarily
attributable to the completion of the two pivotal Phase 3 trials for
Alprox-TD(R) in December 2002 and a significant reduction in expenses and
non-essential personnel under our cash conservation program implemented in
November 2002. We anticipate that net loss in 2004 will increase significantly
with the clinical activities and new drug applicationfiling for Alprox-TD(R),
and planned development activities for other NexACT(R)-based products under
development.
Net Loss applicable to Common Stock. The net loss applicable to common
stock was $20,351,410 or $0.60 per share for 2003, as compared to $27,641,519 or
$1.03 per share for 2002. The decrease in net loss applicable to common stock is
primarily attributable to the completion of the two pivotal Phase 3 trials for
Alprox-TD(R) in December 2002 and a significant reduction in expenses and
non-essential personnel under our cash conservation program implemented in
November 2002. The decrease in operating expenses was partially offset by the
deemed dividend related to the beneficial conversion feature of the preferred
stock as discussed in Note 11 of the consolidated financial statements.
COMPARISON OF RESULTS OF OPERATIONS BETWEEN THE YEARS ENDED DECEMBER 31, 2002
AND 2001.
Revenues. We recorded revenues of $148,028 during the twelve months of
operations in 2002 as compared to $68,089 during the same period in 2001. The
revenues were comprised of royalty payments and payments for the sale of
manufacturing supplies in connection with the sale of Befar(R) in Asia, and from
the first milestone payment received from our Japanese research and development
partner. The 2002 sales of Befar(R) in China were lower than previously
anticipated. Befar(R) along with the currently approved oral erectile
dysfunction product, are currently classified in China as controlled substances,
and their distribution is limited to prescription by certain urologists and
dispensing through hospitals.
18
Cost of Products Sold. Our cost of products sold was $27,030 and
$45,051 and 2002 and 2001, respectively and is attributable to our cost for the
manufacturing supplies sold to our Asian licensee for the production of Befar(R)
in China. Our Asian licensee had sufficient inventory of the manufacturing
supplies during 2002 and made fewer purchases from us.
Research and Development Expenses. Our research and development
expenses for 2002 and 2001 were $21,615,787 and $12,456,384, respectively. The
increase is mostly attributable to the pre-clinical and clinical expenses for
Alprox-TD(R), as well as to additional research and development personnel for
the first ten months of 2002, the increased depreciation for scientific
equipment in our facilities in New Jersey and Kansas and depreciation for the
expansion of our facilities in Robbinsville and in Princeton, NJ.
Selling, General and Administrative Expenses. Our selling, general and
administrative expenses were $6,065,347 during 2002 as compared to $4,770,021
during 2001. The increase is largely attributable to additional expenses for
legal fees related to financing and SEC matters and other operational
activities, educational grants and the expansion of investor and shareholder
relations programs.
Interest Income and Expense. We recognized $243,020 in net interest
expense during 2002 as compared to $1,203,291 in net interest income during
2001. The decrease is a result a significant reduction in our cash position,
lower interest rates in the current period, and an increase in interest expense
due to borrowings under our GE Capital facility and the convertible notes issued
in June 2002.
Net Loss. The net loss was $(27,641,519) or a loss of $1.03 per share
for 2002, compared with $(16,174,861) or a loss of $(0.63) per share for 2001.
The increase in net loss is primarily attributable to the acceleration of U.S.
development activities including U.S. clinical studies and the increase to our
infrastructure to support these activities. We also used our resources to fund
ongoing operations and finance the construction of additional research and
development and manufacturing facilities.
QUARTERLY RESULTS
The following table sets forth selected quarterly financial information
for the years ended December 31, 2002 and 2003. The operating results are not
necessarily indicative of results for any future period.
For the Three Months Ended
- -------------------------------------------------------------------------------------------------------------------------
March 31, 2002 June 30, 2002 September 30, 2002 December 31, 2002
- -------------------------------------------------------------------------------------------------------------------------
Total Revenues $45,281 $21,563 $78,175 $3,009
- -------------------------------------------------------------------------------------------------------------------------
Gross Profit -- -- -- --
- -------------------------------------------------------------------------------------------------------------------------
Loss from Operations ($5,637,103) ($6,924,642) ($6,742,618) ($8,255,773)
- -------------------------------------------------------------------------------------------------------------------------
Net Loss ($5,578,848) ($6,941,103) ($6,875,397) ($8,246,171)
- -------------------------------------------------------------------------------------------------------------------------
Basic & Diluted Loss
Per Share $(0.22) $(0.27) $(0.24) $(.30)
- -------------------------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------
March 31, 2003 June 30, 2003 September 30, 2003 December 31, 2003
- -------------------------------------------------------------------------------------------------------------------------
Total Revenues $1,713 $971 $64,552 $43,507
- -------------------------------------------------------------------------------------------------------------------------
Gross Profit -- -- -- --
- -------------------------------------------------------------------------------------------------------------------------
Loss from Operations ($3,088,667) ($3,413,698) ($2,848,266) ($4,878,535)
- -------------------------------------------------------------------------------------------------------------------------
Net Loss ($3,451,327) ($3,973,247) ($3,181,847) ($6,627,145)
- -------------------------------------------------------------------------------------------------------------------------
Basic & Diluted Loss
Per Share $(0.12) $(0.24) $(0.09) $(.20)
- -------------------------------------------------------------------------------------------------------------------------
19
SUMMARY OF RECENT ACCOUNTING PRONOUNCEMENTS
In January 2003, the Financial Accounting Standards Board ("FASB")
issued Interpretation No. 46 "Consolidation of Variable Interest Entities" ("FIN
46"). Variable Interest Entities ("VIEs") are entities where control is achieved
through means other than voting rights. FIN 46 provides guidance on the
identification of and financial reporting for VIEs. A VIE is required to be
consolidated if the company is subject to the majority of the risk of loss from
the VIE's activities or is entitled to receive a majority of the entity's
residual returns, or both. Certain provisions of FIN 46 were effective during
2003; however generally FIN 46 must be applied to the first reporting period
ending after March 15, 2004. We do not believe the adoption of this
Interpretation will have any impact on the Company's consolidated financial
statements.
In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement
133 on Derivative Instruments and Hedging Activities." This standard amends and
clarifies the accounting for derivative instruments, including certain
derivative instruments embedded in other contracts, and hedging activities under
SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities."
This statement is effective prospectively for contracts entered into or modified
after June 30, 2003, and for hedging relationships designated after June 30,
2003. SFAS No. 149 did not have an impact upon initial adoption and is not
expected to have a material effect on the Company's results of operations,
financial position and cash flows in the future.
In November 2002, the Emerging Issues Task Force (EITF) reached a
consensus on EITF 00-21, "Revenue Arrangements with Multiple Deliverables,"
related to the timing of revenue recognition for arrangements in which goods or
services or both are delivered separately in a bundled sales arrangement. The
EITF requires that when the deliverables included in this type of arrangement
meet certain criteria they should be accounted for separately as separate units
of accounting. This may result in a difference in the timing of revenue
recognition but will not result in a change in the total amount of revenue
recognized in a bundled sales arrangement. The allocation of revenue to the
separate deliverables is based on the relative fair value of each item. If the
fair value is not available for the delivered items then the residual method
must be used. This method requires that the amount allocated to the undelivered
items in the arrangement is their full fair value. This would result in the
discount, if any, being allocated to the delivered items. This consensus is
effective prospectively for arrangements entered into in fiscal periods
beginning after June 15, 2003. EITF 00-21 did not have an impact upon initial
adoption.
In May 2003, the FASB issued Statement No. 150 ("FAS 150"), Accounting
for Certain Financial Instruments with Characteristics of Both Liabilities and
Equity. FAS 150 specifies that instruments within its scope embody obligations
of the issuer and that, therefore, the issuer must classify them as liabilities.
FAS 150 requires issuers to classify as liabilities the following three types of
freestanding financial instruments: (1) mandatory redeemable financial
instruments; (2) obligations to repurchase the issuer's equity shares by
transferring assets and (3) certain obligations to issue a variable number of
shares. FAS 150 defines a "freestanding financial instrument" as a financial
instrument that (1) is entered into separately and apart from any of the
entity's other financial instruments or equity transactions or (2) is entered
into in conjunction with some other transaction and can be legally detached and
exercised on a separate basis. For all financial instruments entered into or
modified after May 31, 2003, FAS 150 is effective immediately. For all other
instruments of public companies (except for the indefinite deferral for certain
mandatorily redeemable interests), FAS 150 goes into effect at the beginning of
the first interim period beginning after June 15, 2003. The Company has
determined that the adoption of FAS 150 did not have a material impact on its
financial statements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We do not hold derivative financial investments, derivative commodity
investments, engage in foreign currency hedging or other transactions that
expose us to material market risk.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
20
INDEX TO FINANCIAL STATEMENTS
PAGE
REPORT OF INDEPENDENT AUDITORS 22
FINANCIAL STATEMENTS
Consolidated Balance Sheets - December 31, 2003 and 2002 23
Consolidated Statements of Operations and Comprehensive Loss for
the years ended December 31, 2003, 2002 and 2001 24
Consolidated Statements of Changes in Stockholders' Equity for
years ended December 31, 2003, 2002 and 2001 25
Consolidated Statements of Cash Flows for the years ended December 31,
2003, 2002 and 2001 26
NOTES TO FINANCIAL STATEMENTS 27
21
REPORT OF INDEPENDENT AUDITORS
To the Board of Directors and Stockholders of NexMed, Inc.
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations and comprehensive loss, of changes in
stockholders' equity and of cash flows present fairly, in all material respects,
the financial position of NexMed, Inc. and its subsidiaries at December 31, 2003
and 2002, and the results of their operations and their cash flows for each of
the three years in the period ended December 31, 2003 in conformity with
accounting principles generally accepted in the United States of America. These
financial statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
auditing standards generally accepted in the United States of America, which
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
The accompanying financial statements have been prepared assuming the Company
will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has suffered recurring losses and negative cash flows
from operations, has limited capital resources and expects to incur future
losses. These factors raise substantial doubt about the Company's ability to
continue as a going concern. Management's plans in regard to those matters are
also described in Note 1. The accompanying financial statements do not include
any adjustments that might result from the outcome of this uncertainty.
/s/ PricewaterhouseCoopers LLP
- ------------------------------
PricewaterhouseCoopers LLP
New York, New York
February 27, 2004
22
NEXMED, INC.
CONSOLIDATED BALANCE SHEETS
- ---------------------------------------------------------------------------------------------------------------
DECEMBER 31,
ASSETS 2003 2002
Current assets
Cash and cash equivalents $ 9,479,214 $ 1,035,149
Marketable securities 1,501,204 539,795
Note receivable 48,341 198,348
Prepaid expenses and other current assets 1,482,426 498,042
------------ ------------
TOTAL CURRENT ASSETS 12,511,185 2,271,334
Fixed assets, net 10,583,733 11,507,564
Note receivable - 48,341
Debt issuance cost, net of accumulated amortization of $794 and $57,575 38,761 312,888
------------ ------------
TOTAL ASSETS $ 23,133,679 $ 14,140,127
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses $ 773,522 $ 4,169,449
Payroll related liabilities 1,273,303 354,992
Deferred revenue 128,708 -
Capital lease obligation 898,861 609,676
------------ ------------
TOTAL CURRENT LIABILITIES 3,074,394 5,134,117
Long term liabilities
Convertible notes payable, net of discount of
$0 and $669,693 6,000,000 4,330,307
Other long term liabilities 458,000 350,000
Capital lease obligations, net of current portion 877,877 1,102,211
------------ ------------
TOTAL LIABILITIES 10,410,271 10,916,635
------------ ------------
Commitments and contingincies (Note 15)
Stockholders' equity:
Preferred stock $.001 par value, 10,000,000 shares authorized,
none issued and outstanding - -
Common stock, $.001 par value, 80,000,000 shares authorized,
40,123,127 and 28,293,719 shares issued and outstanding, respectively 40,124 28,294
Additional paid-in capital 97,924,314 71,381,751
Accumulated other comprehensive loss (163) (101,022)
Deferred compensation (19,332) (97,562)
Accumulated deficit (85,221,535) (67,987,969)
------------ ------------
TOTAL STOCKHOLDERS' EQUITY 12,723,408 3,223,492
------------ ------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 23,133,679 $ 14,140,127
============ ============
The accompanying notes are an integral part of these financial statements.
23
NEXMED, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
- ----------------------------------------------------------------------------------------------------------------------
FOR THE YEAR ENDED
DECEMBER 31,
2003 2002 2001
Revenue
Product sales and royalties $6,206 $63,417 $68,089
Research and development fees 104,537 84,611 -
------------ ------------ ------------
Total revenue 110,743 148,028 68,089
------------ ------------ ------------
Costs and expenses
Cost of products sold - 27,030 45,051
Research and development 8,439,340 21,615,787 12,456,384
Selling, general and administrative 5,900,569 6,065,347 4,770,021
------------ ------------ ------------
TOTAL COSTS AND EXPENSES 14,339,909 27,708,164 17,271,456
------------ ------------ ------------
Loss from operations (14,229,166) (27,560,136) (17,203,367)
------------ ------------ ------------
Other income (expense)
Other (expense) (152,867) (81,008) (174,785)
Interest income 75,574 141,266 1,236,845
Interest expense (3,159,338) (384,286) (33,554)
------------ ------------ ------------
Total other income (expense) (3,236,631) (324,028) 1,028,506
------------ ------------ ------------
Loss before benefit from income taxes (17,465,797) (27,884,164) (16,174,861)
Benefit from income taxes 232,231 242,645 -
------------ ------------ ------------
NET LOSS (17,233,566) (27,641,519) (16,174,861)
------------ ------------ ------------
Deemed dividend to preferred shareholders
from beneficial conversion feature (2,942,656) - -
Preferred dividend (175,188) - -
------------ ------------ ------------
NET LOSS APPLICABLE TO COMMON STOCK (20,351,410) (27,641,519) (16,174,861)
------------ ------------ ------------
Other comprehensive loss
Foreign currency translation adjustments 3,348 (223) 36
Unrealized gain (loss) on marketable securities (3,646) 2,562 6,006
------------ ------------ ------------
COMPREHENSIVE LOSS $(17,233,864) $(27,639,180) $(16,168,819)
============ ============ ============
Basic and diluted loss per share $ (.60) $ (1.03) $ (.63)
============ ============ ============
Weighted average common shares outstanding
used for basic and diluted loss per share 33,649,774 26,937,200 25,486,465
============ ============ ============
The accompanying notes are an integral part of these financial statements.
24
NEXMED, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
- ------------------------------------------------------------------------------------------------------------------------------------
COMMON COMMON PREFERRED PREFERRED ADDITIONAL
STOCK STOCK STOCK STOCK PAID-IN ACCUMULATED
(SHARES) (AMOUNT) (SHARES) (AMOUNT) CAPITAL DEFICIT
Balance at January 1, 2001 25,147,384 $25,147 $63,009,161 ($24,171,589)
Issuance of common stock
upon exercise of stock options 189,550 190 382,010 -
Issuance of common stock
upon exercise of warrants, net 200,000 200 599,800 -
Issuance of common stock for services 5,000 5 27,495 -
Issuance of compensatory options and
warrants to consultants - - 482,770 -
Capital contribution - - 37,602 -
Amortization of deferred compensation
expense - - - -
Unrealized loss from available-for-
sale securities - - - -
Cumulative translation adjustment - - - -
Net loss - - - (16,174,861)
---------- ------ ---- ---- ----------- ------------
Balance at December 31, 2001 25,541,934 25,542 - - 64,538,838 (40,346,450)
Issuance of common stock from private
placement, net of commission paid 2,666,670 2,667 5,729,204 -
Issuance of common stock
upon exercise of stock options 53,000 53 18,447 -
Issuance of compensatory options and
warrants to consultants - - 71,840 -
Issuance of common stock to Board
of Directors 32,115 32 56,468 -
Issuance of common stock to
employees as bonus - - 104,392 -
Issuance of warrants as debt
issuance cost - - 66,861 -
Discount on convertible note payable - - 795,701 -
Amortization of deferred compensation
expense - - - -
Unrealized loss from available-for-
sale securities - - - -
Cumulative translation adjustment - - - -
Net loss - - - (27,641,519)
---------- ------ ---- ---- ----------- ------------
Balance at December 31, 2002 28,293,719 28,294 - - 71,381,751 (67,987,959)
Issuance of common stock from private
placement, net of commission paid 3,126,655 3,127 - - 10,246,854 -
Issuance of common stock upon
exercise of options and warrants 750,795 751 - - 916,011 -
Issuance of compensatory options
and warrants to consultants - - 253,402 -
Issuance of common stock to Board
of Directors 15,268 15 - - 54,988 -
Stock based compensation to employees 186,938 187 - - 15,832 -
Issuance of preferred stock with
detachable warrants and beneficial
conversion feature, net of issue
costs - - 800 1 7,396,623 -
Issuance fo common stock upon
conversion of preferred stock,
including dividends paid in stock 5,170,907 5,171 (800) (1) (5,171) -
Discount on convertible notes,
including beneficial conversion
features and fair value of
detachable warrants - - - - 2,141,417 -
Issuance of common stock upon
conversion of convertible notess,
including interest paid in stock 2,603,160 2,603 - - 5,641,970 -
Stock surrendered by officer and
retired in payment of loan (24,315) (24) - - (119,363) -
Realized loss on sale of securities - - - - - -
Amortization of deferred
compensation expense - - - - - -
Unrealized loss from available-for-
sale securities - - - - - -
Cumulative translation adjustment - - - - - -
Net loss - - - - - (17,233,566)
---------- ------ ---- ---- ----------- ------------
Balance at December 31, 2003 40,123,127 $40,124 - - $97,924,314 ($85,221,353)
ACCUMULATED OTHER
COMPREHENSIVE INCOME (LOSS)
---------------------------
UNREALIZED
FOREIGN LOSS ON TOTAL
DEFERRED CURRENCY MARKETABLE STOCKHOLDERS'
COMPENSATION TRANSLATION SECURITIES EQUITY
Balance at January 1, 2001 ($9,141) $322 ($109,725) $38,744,175
Issuance of common stock
upon exercise of stock options - - - 382,200
Issuance of common stock
upon exercise of warrants, net - - - 600,000
Issuance of common stock for services - - - 27,500
Issuance of compensatory options and
warrants to consultants - - - 482,770
Capital contribution - - - 37,602
Amortization of deferred compensation
expense 2,437 - - 2,437
Unrealized loss from available-for-
sale securities - - 6,006 6,006
Cumulative translation adjustment - 36 - 36
Net loss - - - (16,174,861)
---------- ------ ----------- ------------
Balance at December 31, 2001 (6,704) 358 (103,719) 24,107,865
Issuance of common stock from private
placement, net of commission paid - - - 5,731,871
Issuance of common stock
upon exercise of stock options - - - 18,500
Issuance of compensatory options and
warrants to consultants - - - 71,840
Issuance of common stock to Board
of Directors (15,000) - - 41,500
Issuance of common stock to
employees as bonus (78,294) - - 26,098
Issuance of warrants as debt
issuance cost - - - 66,861
Discount on convertible note payable - - - 795,701
Amortization of deferred compensation
expense 2,436 - - 2,436
Unrealized loss from available-for-
sale securities - - 2,562 2,562
Cumulative translation adjustment - (223) - (223)
Net loss - - - (27,641,519)
---------- ------ ----------- ------------
Balance at December 31, 2002 (97,562) 135 (101,157) 3,223,492
Issuance of common stock from private
placement, net of commission paid - - - 10,249,981
Issuance of common stock upon
exercise of options and warrants - - - 916,762
Issuance of compensatory options
and warrants to consultants - - - 253,402
Issuance of common stock to Board
of Directors (35,000) - - 20,003
Stock based compensation to employees 78,294 - - 94,313
Issuance of preferred stock with
detachable warrants and beneficial
conversion feature, net of issue
costs - - - 7,397,424
Issuance fo common stock upon
conversion of preferred stock,
including dividends paid in stock - - - (801)
Discount on convertible notes,
including beneficial conversion
features and fair value of
detachable warrants - - - 2,141,417
Issuance of common stock upon
conversion of convertible notess,
including interest paid in stock - - - 5,644,573
Stock surrendered by officer and
retired in payment of loan - - - (119,387)
Realized loss on sale of securities - - 101,157 101,157
Amortization of deferred
compensation expense 34,936 - - 34,936
Unrealized loss from available-for-
sale securities - - (3,646) (3,646)
Cumulative translation adjustment - 3,348 - 3,348
Net loss - - - (17,233,566)
---------- ------ ----------- ------------
Balance at December 31, 2003 ($19,332) $3,483 ($3,646) $12,723,408
The accompanying notes are an integral part of these financial statements.
25
NEXMED, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
- -----------------------------------------------------------------------------------------------------------------------
FOR THE YEAR ENDED
DECEMBER 31,
2003 2002 2001
Cash flows from operating activities
Net loss $(17,233,566) $(27,641,519) $(16,174,861)
Adjustments to reconcile net loss to net cash
used in operating activities
Depreciation and amortization 1,250,667 882,854 527,011
Non-cash interest, amortization of debt discount and
deferred financing costs 3,166,072 183,582 -
Non-cash compensation expense 408,636 141,874 512,707
Non-cash insurance expense (income) 3,501 (2,155) 15,044
Net loss on sale of marketable securities 94,824 142,291 -
Loss on disposal of property and equipment 114,542 - 112,687
Decrease (increase) in prepaid expense and other assets (1,109,109) 381,449 (77,019)
Increase in deferred revenue 128,708 - -
Increase in payroll related liabilities 918,311 354,992 -
(Decrease) increase in other long term liabilities 108,000 350,000 -
(3,395,927) 1,974,719 949,223
------------ ------------ ------------
NET CASH USED IN OPERATING ACTIVITIES (15,545,341) (23,231,913) (14,135,208)
------------ ------------ ------------
Cash flows from investing activities
Capital expenditures (441,297) (4,698,900) (4,933,917)
Issuance of note receivable - (309,575) -
Proceeds from collection of note receivable 198,348 62,886 -
Purchases of certificates of deposits and marketable securities (1,504,850) (3,610,747) (5,878,345)
Proceeds from sale/redemption of certificates of deposits and
marketable securities 545,200 8,763,279 8,126,732
------------ ------------ ------------
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES (1,202,599) 206,943 (2,685,530)
------------ ------------ ------------
Cash flows from financing activities
Issuance of common stock, net of offering costs 11,166,741 5,750,371 982,200
Issuance of preferred stock, net of offering costs 7,396,623 - -
Return of gain on stock by former executive - - 37,602
Issuance of notes payable, net of debt issue costs 7,510,445 4,696,399 -
Repayment of notes payable (950,000) - -
Proceeds from Capital Lease financing for equipment 738,731 1,111,427 1,113,459
Principal payments on capital lease obligations (673,883) (411,658) (101,341)
------------ ------------ ------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 25,188,657 11,146,539 2,031,920
------------ ------------ ------------
Effect of foreign exchange on cash 3,348 (223) 36
------------ ------------ ------------
Net increase (decrease) in cash and cash equivalents 8,444,065 (11,878,654) (14,788,782)
Cash and cash equivalents
Beginning of period 1,035,149 12,913,803 27,702,585
------------ ------------ ------------
End of period $ 9,479,214 $ 1,035,149 $12,913,803
============ ============ ============
Cash paid for interest $ 142,850 $ 196,955 $ 33,554
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment acquired through capital lease obligations $ 738,731 $ 1,111,427 $ 1,113,459
Conversion of debt to common stock 5,600,000 - -
Payment of interest in common stock 275,448 - -
Conversion of preferred stock to common stock 2,019,826 - -
Preferred stock dividend paid in common stock 175,188 - -
Amortization of debt discount 2,811,110 126,006 -
Deemed dividend to preferred shareholders 2,942,656 - -
Deemed dividend to warrant holders 120,717 - -
Repayment of officer loan in stock 119,387
The accompanying notes are an integral part of these financial statements.
26
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
1. ORGANIZATION AND BASIS OF PRESENTATION
The Company was incorporated in Nevada in 1987. In January 1994, the
Company began research and development of a device for the treatment of
herpes simplex. The Company, since 1995, has conducted research and
development both domestically and abroad on proprietary pharmaceutical
products, with the goal of growing through acquisition and development of
pharmaceutical products and technology.
The accompanying financial statements have been prepared on a basis which
contemplates the realization of assets and the satisfaction of liabilities
and commitments in the normal course of business. The Company has an
accumulated deficit of $85,221,535 at December 31, 2003 and expects that it
will incur additional losses in the future completing the research,
development and commercialization of its technologies. These circumstances
raise substantial doubt about the Company's ability to continue as a going
concern. Management anticipates that it will require additional financing,
which it is actively pursuing, to fund operations, including continued
research, development and clinical trials of the Company's product
candidates. Although management continues to pursue these plans, there is
no assurance that the Company will be successful in obtaining financing on
terms acceptable to the Company. If the Company is unable to obtain
additional financing, operations will need to be discontinued. The
financial statements do not include any adjustments that might result from
the outcome of this uncertainty.
2. SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES
Significant accounting principles followed by the Company in preparing its
financial statements are as follows:
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company
and its majority and wholly owned subsidiaries. All significant
intercompany accounts and transactions have been eliminated.
RECLASSIFICATIONS
Reclassifications of certain amounts for prior years have been recorded to
conform to the current year presentation.
TRANSLATION OF FOREIGN CURRENCIES
The functional currency of the Company's foreign subsidiary located in Hong
Kong is the local currency. Assets and liabilities of the Company's foreign
subsidiaries are translated to United States dollars based on exchange
rates at the end of the reporting period. Income and expense items are
translated at average exchange rates prevailing during the reporting
period. Translation adjustments are accumulated in a separate component of
stockholder's equity. Transaction gains or losses are included in the
determination of operating results.
CASH AND CASH EQUIVALENTS
For purposes of the balance sheets and the statements of cash flows, cash
equivalents represent all highly liquid investments with an original
maturity date of three months or less.
MARKETABLE SECURITIES
Marketable securities consist of high quality corporate and government
securities, which have original maturities of more than three months at the
date of purchase and less than one year from the
27
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
date of the balance sheet, and equity investments in publicly-traded
companies. The Company classifies all debt securities and equity securities
with readily determinable market value as "available for sale" in
accordance with SFAS No. 115, "Accounting for Certain Investments in Debt
and Equity Securities." These investments are carried at fair market value
with unrealized gains and losses reported as a separate component of
stockholders' equity. Gross unrealized losses were $3,646 and $103,359 for
2003 and 2002, respectively. All unrealized losses were less than 12 months
in nature. Gross realized gains from the sales of securities classified as
available for sale were $17,016, $143,971, and $269,058 for 2003, 2002 and
2001 respectively. Gross realized losses were $111,840, $1,680, and
$263,052 respectively. For the purpose of determining realized gains and
losses, the cost of securities sold was based on specific identification.
The Company reviews investments on a quarterly basis for reductions in
market value that are other than temporary. When such reductions occur, the
cost of the investment is adjusted to its fair value through a charge to
other income (expense) in the periods incurred.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying value of cash and cash equivalents, notes payable and accounts
payable and accrued expenses approximates fair value due to the relatively
short maturity of these instruments.
FIXED ASSETS
Property and equipment are stated at cost less accumulated depreciation.
Depreciation of equipment and furniture and fixtures is provided on a
straight-line basis over the estimated useful lives of the assets,
generally three to ten years. Depreciation of buildings is provided on a
straight-line basis over its estimated useful life of 31 years.
Amortization of leasehold improvements is provided on a straight-line basis
over the shorter of their estimated useful life or the lease term. The
costs of additions and betterments are capitalized, and repairs and
maintenance costs are charged to operations in the periods incurred.
LONG-LIVED ASSETS
The Company reviews for the impairment of long-lived assets whenever events
or circumstances indicate that the carrying amount of an asset may not be
recoverable. An impairment loss would be recognized when estimated
undiscounted future cash flows expected to result from the use of the asset
and its eventual disposition is less than its carrying amount. If such
assets are considered impaired, the amount of the impairment loss
recognized is measured as the amount by which the carrying value of the
asset exceeds the fair value of the asset, fair value being determined
based upon discounted cash flows or appraised values, depending on the
nature of the asset. No such impairment losses have been recorded by the
Company during 2003, 2002 or 2001.
REVENUE RECOGNITION
Revenues from product sales are recognized upon delivery of products to
customers, less allowances for estimated returns and discounts. Royalty
revenue is recognized upon the sale of the related products, provided the
royalty amounts are fixed or determinable and the amounts are considered
collectible.
Revenues earned under research and development contracts are recognized in
accordance with the cost-to-cost method outlined in Staff Accounting
Bulletin No. 101 whereby the extent of progress toward completion is
measured on the cost-to-cost basis; however, revenue recognized at any
point will not exceed the cash received. When the current estimates of
total contract revenue and contract cost indicate a loss, a provision for
the entire loss on the contract is made in the period which it becomes
probable. All costs related to these agreements are expensed as incurred
and classified
28
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
within "Research and development" expenses in the Condensed Consolidated
Statement of Operations and Comprehensive Income.
RESEARCH AND DEVELOPMENT
Research and development costs are expensed as incurred and include the
cost of salaries, building costs, utilities, allocation of indirect costs,
and expenses to third parties who conduct research and development,
pursuant to development and consulting agreements, on behalf of the
Company.
INCOME TAXES
Income taxes are accounted for under the asset and liability method.
Deferred income taxes are recorded for temporary differences between
financial statement carrying amounts and the tax bases of assets and
liabilities. Deferred tax assets and liabilities reflect the tax rates
expected to be in effect for the years in which the differences are
expected to reverse. A valuation allowance is provided if it is more likely
than not that some or all of the deferred tax assets will not be realized.
LOSS PER COMMON SHARE
Basic earnings per share ("Basic EPS") is computed by dividing income
available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted earnings per share ("Diluted
EPS") gives effect to all dilutive potential common shares outstanding
during the period. The computation of Diluted EPS does not assume
conversion, exercise or contingent exercise of securities that would have
an antidilutive effect on per share amounts.
At December 31, 2003, 2002 and 2001, outstanding options to purchase
5,414,617, 4,750,755, and 3,834,575 shares of common stock, respectively,
with exercise prices ranging from $.50 to $16.25 have been excluded from
the computation of diluted loss per share as they are antidilutive.
Outstanding warrants to purchase 7,272,261, 2,044,908, and 2,206,549 shares
of common stock, respectively, with exercise prices ranging from $1.00 to
$16.20 have also been excluded from the computation of diluted loss per
share as they are antidilutive. Promissory notes convertible into 923,077
and 1,225,490 shares of common stock (see Note 6) in 2003 and 2002
respectively have also been excluded from the computation of diluted loss
per share as they are antidilutive.
ACCOUNTING FOR STOCK BASED COMPENSATION
As provided by SFAS 123, Accounting for Stock-Based Compensation ("SFAS
123"), the Company has elected to continue to account for its stock-based
compensation programs according to the provisions of Accounting Principles
Board Opinion No. 25, "Accounting for Stock Issued to Employees."
Accordingly, compensation expense has been recognized to the extent of
employee or director services rendered based on the intrinsic value of
compensatory options or shares granted under the plans. The Company has
adopted the disclosure provisions required by SFAS 123.
29
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Had the company's stock-based compensation been determined by the
fair-value based method of SFAS 123, "Accounting for Stock-Based
Compensation," the company's net loss and loss per share would have been as
follows:
FOR THE YEAR ENDED
2003 2002 2001
Net loss applicable to common stock, as reported $(20,351,410) $(27,641,519) $(16,174,861)
Add: Stock-based compensation expense included
in reported net loss 408,636 141,874 512,707
Deduct: Total stock-based compensation expense determined
under fair-value based method for all awards (2,211,685) (2,591,717) (2,605,307)
---------------------------------------------
Proforma net loss applicable to common stock $(22,154,459) $(30,091,362) $(18,267,461)
=============================================
Basic and diluted loss per share:
As reported $(0.60) $(1.03) $(0.63)
Proforma $(0.66) $(1.12) $(0.72)
Additional disclosures required under SFAS 123 are presented in Note 9.
CONCENTRATION OF CREDIT RISK
From time to time, the Company maintains cash in bank accounts that exceed
the FDIC insured limits. The Company has not experienced any losses on its
cash accounts.
COMPREHENSIVE LOSS
We have recorded comprehensive loss in accordance with Statement of
Financial Accounting Standards ("SFAS") No. 130, "Reporting Comprehensive
Income" ("SFAS 130"), which requires the presentation of the components of
comprehensive loss in the Company's financial statements. Comprehensive
loss is defined as the change in the Company's equity during a financial
reporting period from transactions and other circumstances from non-owner
sources (including cumulative translation adjustments and unrealized
gains/losses on available for sale securities). Accumulated other
comprehensive (loss) income included in the Company's balance sheet is
comprised of translation adjustments from the Company's foreign
subsidiaries and unrealized gains and losses on investment in marketable
securities.
ACCOUNTING ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates that
affect the reported amounts of assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses
during the reporting period. The Company's most significant estimates
relate to the valuation of its long-lived
30
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
assets and estimated cost to complete under its research contracts. Actual
results may differ from those estimates.
RECENT ACCOUNTING PRONOUNCEMENTS
In January 2003, the Financial Accounting Standards Board ("FASB") issued
Interpretation No. 46 "Consolidation of Variable Interest Entities" ("FIN
46"). Variable Interest Entities ("VIEs") are entities where control is
achieved through means other than voting rights. FIN 46 provides guidance
on the identification of and financial reporting for VIEs. A VIE is
required to be consolidated if the company is subject to the majority of
the risk of loss from the VIE's activities or is entitled to receive a
majority of the entity's residual returns, or both. Certain provisions of
FIN 46 were effective during 2003; however generally FIN 46 must be applied
to the first reporting period ending after March 15, 2004. We do not
believe the adoption of this Interpretation will have any impact on the
Company's consolidated financial statements.
In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement 133 on
Derivative Instruments and Hedging Activities." This standard amends and
clarifies the accounting for derivative instruments, including certain
derivative instruments embedded in other contracts, and hedging activities
under SFAS No. 133, "Accounting for Derivative Instruments and Hedging
Activities." This statement is effective prospectively for contracts
entered into or modified after June 30, 2003, and for hedging relationships
designated after June 30, 2003. SFAS No. 149 did not have an impact upon
initial adoption and is not expected to have a material effect on the
Company's results of operations, financial position and cash flows in the
future.
In November 2002, the Emerging Issues Task Force (EITF) reached a consensus
on EITF 00-21, "Revenue Arrangements with Multiple Deliverables," related
to the timing of revenue recognition for arrangements in which goods or
services or both are delivered separately in a bundled sales arrangement.
The EITF requires that when the deliverables included in this type of
arrangement meet certain criteria they should be accounted for separately
as separate units of accounting. This may result in a difference in the
timing of revenue recognition but will not result in a change in the total
amount of revenue recognized in a bundled sales arrangement. The allocation
of revenue to the separate deliverables is based on the relative fair value
of each item. If the fair value is not available for the delivered items
then the residual method must be used. This method requires that the amount
allocated to the undelivered items in the arrangement is their full fair
value. This would result in the discount, if any, being allocated to the
delivered items. This consensus is effective prospectively for arrangements
entered into in fiscal periods beginning after June 15, 2003. EITF 00-21
did not have an impact upon initial adoption.
In May 2003, the FASB issued Statement No. 150 ("FAS 150"), Accounting for
Certain Financial Instruments with Characteristics of Both Liabilities and
Equity. FAS 150 specifies that instruments within its scope embody
obligations of the issuer and that, therefore, the issuer must classify
them as liabilities. FAS 150 requires issuers to classify as liabilities
the following three types of freestanding financial instruments: (1)
mandatory redeemable financial instruments; (2) obligations to repurchase
the issuer's equity shares by transferring assets and (3) certain
obligations to issue a variable number of shares. FAS 150 defines a
"freestanding financial instrument" as a financial instrument that (1) is
entered into separately and apart from any of the entity's other financial
instruments or equity transactions or (2) is entered into in conjunction
with some other transaction and can be legally detached and exercised on a
separate basis. For all financial instruments entered into or modified
after May 31, 2003, FAS 150 is effective immediately. For all other
instruments of public companies (except for the indefinite deferral for
certain mandatorily redeemable interests),
31
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
FAS 150 goes into effect at the beginning of the first interim period
beginning after June 15, 2003. The Company has determined that the adoption
of FAS 150 did not have a material impact on its financial statements.
3. RESEARCH AND DEVELOPMENT AGREEMENTS
In November 2003, the Company entered into an agreement with a Japanese
pharmaceutical company whereby NexMed will provide contract development
services for an innovative topical treatment for a form of herpes. The
Company received $100,000 as a signing payment, of which, it has recognized
revenue of approximately $13,000 in 2003 and has deferred approximately
$87,000 in revenue that is expected to be recognized upon completion of the
first phase of development in the first quarter of 2004. Pending the
satisfactory completion of certain milestones, the Company will receive
additional payments from the development partner.
In November 2003, the Company entered into an R&D agreement with a Japanese
pharmaceutical company to develop a new local anesthetics gel designed for
pain relief associated with dental procedures, superficial skin surgery and
skin graft harvesting, and needle insertions. Pursuant to the terms of the
agreement, the Company retains the rights to manufacture and commercialize
the new product worldwide except in Japan. The Company recognized revenue
of approximately $5,000 in 2003 and has deferred approximately $41,000 in
revenue that is expected to be recognized upon completion of the first
phase of development in the first quarter of 2004. Pending the satisfactory
completion of certain milestones, the Company expects to receive additional
payments from the development partner.
In October 2003, the Company entered into an R&D agreement with a Japanese
Pharmaceutical company to develop a tape/patch treatment for chronic pain.
Pursuant to the terms of the agreement, the Company retains the rights to
manufacture and commercialize the new product worldwide except in Japan.
The Company recognized revenue of approximately $21,000 in 2003. The
Company completed the first phase of development but the development
partner decided to suspend all remaining development work on this project
due to new regulatory developments in Japan. As such, there will be no
additional revenue from the Japanese pharmaceutical company should the
Company continue to develop this product further.
In August 2003, the Company entered into an R&D agreement with a Japanese
pharmaceutical company to develop NM 20138, a new once-a-day patch
treatment for bronchial asthma, which incorporates an off-patent
anti-asthmatic drug compound and the NexACT(R) technology. Pursuant to the
terms of the agreement, the Company retains the rights to manufacture and
commercialize the new product worldwide except in Japan. The Company
recognized revenue of approximately $21,000 in 2003. The Company completed
the first phase of development but the partner elected not to take the
project to the next stage of development due to proprietary reasons. As
such, there will be no additional revenue from the Japanese pharmaceutical
company should the Company continue to develop this product further.
In August 2002, the Company entered into a research and development
agreement with a Japanese pharmaceutical company. Pursuant to the terms of
this agreement, the Company will develop a new tape/patch treatment for
urinary dysfunction which incorporates the Japanese partner's proprietary
drug compound with the NexACT(R) technology. Pursuant to the terms of the
agreement, the Company retains the rights to manufacture and commercialize
the new product worldwide except in Japan. The Company recognized revenue
of approximately $42,000 and $85,000 in 2003 and 2002
32
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
respectively. The Company completed the first phase of development and the
Japanese pharmaceutical company elected not to take the project to the next
stage of development due to proprietary reasons. As such, there will be no
additional revenue from the Japanese pharmaceutical company should the
Company continue to develop this product further.
4. NOTE RECEIVABLE
The Company has advanced its Asian licensee funds to finance the purchase
of certain equipment. In February 2002, the Company received a note, in the
original principal amount of $309,575, to evidence these advances. The note
bears interest at 6% per annum and is payable in monthly installments of
principal and interest through February 2004. As of December 31, 2003,
$48,341 of the principal amount remained outstanding.
5. FIXED ASSETS
Fixed assets at December 31, 2003 and 2002 are comprised of the following:
2003 2002
Land 363,909 363,909
Building 7,210,118 7,116,929
Machinery and equipment 1,191,707 1,761,926
Capital lease - Equipment 2,881,220 2,224,886
Computer software 565,158 565,158
Furniture and fixtures 343,971 343,971
Leasehold improvements 637,907 634,624
----------- -----------
13,193,990 13,011,403
Less: accumulated depreciation (2,610,257) (1,503,839)
----------- -----------
$10,583,733 $11,507,564
=========== ===========
Depreciation and amortization expense was $1,250,667, $882,855, and
$527,011 for 2003, 2002 and 2001 respectively, of which $424,778, $268,716
and $74,230 related to capital leases for the respective years. Accumulated
amortization of assets under capital leases was $796,144 and $371,366 at
December 31, 2003 and 2002, respectively.
6. NOTES PAYABLE
On December 12, 2003, the Company issued convertible notes (the "2003
Notes") with a face value of $6 million. The 2003 Notes are payable on May
31, 2007 and are collateralized by the Company's manufacturing facility in
East Windsor, New Jersey. The Notes are initially convertible into shares
of the Company's common stock at a conversion price initially equal to
$6.50 per share (923,077 shares). The conversion price will be adjusted on
June 14, 2004 to the volume weighted average price of the Company's stock
over the six month period beginning December 15, 2003 and ending on June
14, 2004 but will be no greater than $6.50 and no less than $5.00. Interest
accretes on the 2003 Notes on a semi-annual basis at a rate of 5% per
annum, and the Company may pay
33
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
such amounts in cash or by effecting the automatic conversion of such
amount into the Company's common stock at a 10% discount to the then
average market prices.
On June 11, 2002, the Company issued Notes with a face value of $5 million
to two purchasers ("the 2002 Notes"). Outstanding principal and accrued
interest on the 2002 Notes were payable on November 30, 2005 and were
collateralized by the Company's manufacturing facility in East Windsor, New
Jersey. The Notes were initially convertible into shares of the Company's
common stock at a conversion price equal to $4.08 per share (1,225,490
shares). The terms of the 2002 Notes provided that, if the Company were to
issue shares of its common stock subsequent to September 30, 2002 at per
share prices lower than the conversion price of the 2002 Notes, the
conversion price may be adjusted lower. Interest accretes on the 2002 Notes
on a semi-annual basis at a rate of 5% per annum, and the Company had the
option topay such amounts in cash or by effecting the automatic conversion
of such amount into the Company's common stock at a 10% discount to the
then average market prices. Subject to certain exceptions, the Company had
prepayment rights for portions of the principal amount, payable in cash or
by conversion into common stock at a 10% discount to average market prices.
The purchasers also received warrants to purchase 389,408 shares of common
stock (the "Warrants") at an exercise price equal to the initial conversion
price of the Notes and a term of five years from the date of issuance. The
Company valued the warrants using the Black-Scholes pricing model and
allocated to the warrants $795,701 of the proceeds from the 2002 Notes,
based upon the relative fair value of the 2002 Notes and the Warrants, and
has recorded such amount as discount on the 2002 Notes. The discount was
amortized to interest expense over the term of the 2002 Notes. Assumptions
utilized in the Black-Scholes model to value the Warrants were: exercise
price of $4.08 per share; fair value of the Company's common stock on date
of issuance of $3.00 per share; volatility of 100%; term of five years and
a risk-free interest rate of 3%.
On February 4, 2003 the terms of the 2002 Notes were amended. In order to
induce the holders to exercise all of their outstanding warrants in full,
the Company agreed to reduce the warrant exercise price to $1.37
(originally $4.08) per share. In addition, the Company also agreed to
reduce the conversion price of the 2002 Notes to $2.75 from $4.08 per
share. Pursuant to the amendment, all of the warrants were exercised on
February 4, 2003 and the Company received cash proceeds of $533,489 from
such exercise. Pursuant to the original terms of the 2002 Notes, the
conversion price was further reduced to $2.71 as a result of the March 2003
private placement. As a result of the February 2003 amendments and the
Company's sale of securities in March 2003, the Company recorded a deemed
dividend to the warrant holders of $120,717, representing the incremental
fair value of the warrant as a result of reducing the exercise price, and
recorded an additional discount on the 2002 Notes of $1,305,148 reflecting
the changes to the conversion price. The latter was being amortized to
interest expense over the remaining term of the 2002 Notes.
As a result of the April and July 2003 placements, the conversion price of
the 2002 Notes was further reduced to $2.38 and the Company recorded an
additional discount of $763,727, which was amortized to interest expense
over the remaining term of the 2002 Notes.
In April and October 2003, respectively, pursuant to the terms of the 2002
Notes, the Company issued 102,179 shares and 25,253 shares of its common
stock as payment of an aggregate of $217,411 in interest on the 2002 Notes.
On June 17, 2003, $500,000 of the convertible note was converted to common
stock. On July 14 and September 18, 2003, respectively, an additional
$650,000 and $150,000 of the 2002 Notes were
34
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
converted to common stock and in October and November 2003 an aggregate of
$1,450,000 of the 2002 Notes was converted to common stock. In connection
with such conversions, one of the noteholders converted the full amount of
its note. In addition, on October 15, 2003, pursuant to the terms of the
2002 Notes, the Company issued a conversion notice to the other holder to
convert $250,000 of its note to common stock at a conversion price equal to
the 10 day average market price prior to November 3, 2003 ($4.57). The
holder subsequently issued a blocking notice pursuant to the terms of the
2002 Notes which prevents the Company from issuing further conversion
notices to the holder for one year. At closing for the 2003 Notes, the
purchasers converted the remaining principal balance at December 12, 2003
of $2,000,000 on the 2002 Notes into shares of the Company's common stock
at a conversion price of $2.38 per share. A total of 2,047,888 shares of
common stock were issued in connection with the above-mentioned conversions
of the 2002 Notes in 2003. The Company also issued 18,464 shares of common
stock as payment of all unpaid accrued interest on the Note through
December 12, 2003. In January and February 2003, the Company issued two
short-term promissory notes, for an aggregate principal amount of $600,000,
to one accredited investor. These promissory notes bore interest at 12% per
annum and were convertible at the option of the noteholders into the
Company's securities at such time as the Company closed a private placement
of its securities. On March 21, 2003, the Company closed a private
placement of its shares of common stock at $1.50 per share and the
noteholder elected to convert the outstanding $600,000 in principal and
$14,064 in accrued interest into 409,376 shares of our common stock and
307,032 warrants to purchase shares of our common stock.
In March 2003, the Company issued a short-term promissory note due May 4,
2003 in the principal amount of $500,000 to an accredited investor. This
promissory note bore interest at 15% per annum and provided for two-year
warrants to purchase 50,000 shares of our common stock, at an exercise
price of $2.00 per share. The Company has valued the warrants using the
Black-Scholes pricing model assuming a risk free interest rate of 1.35%,
dividend yield of 0% and expected volatility of 100% and allocated $42,000
of the proceeds from the note, based upon the relative fair value of the
note and the warrants, to the warrants and has recorded such amount as
discount on the note. Pursuant to the terms of the note, the due date of
the note was extended one month on May 4, 2003 to June 4, 2003 at an
increased interest rate of 18%. On May 9, 2003, the Company repaid $250,000
of the promissory note and the remaining balance due of $250,000 was repaid
on June 17, 2003.
In April 2003 and June 2003, the Company issued two short-term promissory
notes due June 9, 2003 for $250,000 and $200,000 to an accredited investor.
The promissory notes bore interest at 15% per annum. The principal of both
notes was repaid on June 17, 2003.
For the years ended December 31, 2003 and 2002, the Company recorded
amortization of the debt discount of $2,811,110 and $126,006, respectively
and amortization of loan closing costs of $82,807 and $57,575,
respectively.
7. LINE OF CREDIT
In February 2001, the Company entered into a financial arrangement with GE
Capital Corporation for a line of credit, which provided for the financing
of up to $5 million of equipment (i) for its new East Windsor, NJ
manufacturing facility and (ii) for its expanded corporate and laboratory
facilities in Robbinsville, NJ. Equipment financed through this facility
was in the form of a 42 month capital lease. As of December 31, 2002, the
Company had financed $1,113,459 of equipment purchases under the GE credit
line. The $5 million credit line expired in March 2002, and as of
35
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
December 31, 2003, there was an outstanding balance due GE of $407,494
under this facility. This balance is payable in monthly installments
through various dates in 2004.
In January 2002, GE approved a new credit line, which provided for the
financing of up to $3 million of equipment and expired on December 31,
2002. During 2002, the Company accessed $1,111,427 of the credit line. As
of December 31, 2003, there was an outstanding balance due GE of $694,718
under the January 2002 facility. Balances due are payable in 42 monthly
installments from date of take-down. The $3 million credit line expired on
December 31, 2002.
In July 2003, GE approved a new credit line, which expires in July 2004 and
provides for the financing of up to $1.85 million of equipment. During
2003, the Company accessed $738,731 of the credit line. As of December 31,
2003, there was an outstanding balance due GE of $674,526 under the July
2003 facility, payable in 36 monthly installments from the date of
take-down.
8. RELATED PARTY TRANSACTIONS
In April 2002, the Company advanced $150,000 to James L. Yeager, Ph.D., the
Company's Senior Vice President for Scientific Affairs and a director. The
note was repaid in full by December 31, 2003. The advance was evidenced by
a promissory note, which bore interest at 5% per annum and was due on
November 15, 2002. The note was not paid in full by November 15, 2002 and
went into default. According to the terms of the note, upon default the
interest rate increased to 15% per annum. Interest due on the promissory
note at the default rate of 15% was paid on a timely basis. On October 16,
2003, Dr. Yeager surrendered 24,315 shares of the Company's common stock to
the Company, which the Company then retired, as payment in full of the
promissory note. The number of shares surrendered was determined by
dividing the outstanding principal and accrued interest on the promissory
note of $119,386.98 by the closing sale price of the Company's common stock
on October 16, 2003. The note receivable was included in the December 31,
2002 Condensed Consolidated Balance Sheet under "Prepaid expenses and other
assets".
9. STOCK OPTIONS
During October 1996 the Company adopted a Non-Qualified Stock Option Plan
("Stock Option Plan") and reserved 100,000 shares of common stock for
issuance pursuant to the Plan. During December 1996, the Company also
adopted The NexMed, Inc. Stock Option and Long-Term Incentive Compensation
Plan ("the Incentive Plan") and The NexMed, Inc. Recognition and Retention
Stock Incentive Plan ("the Recognition Plan"). A total of 2,000,000 shares
were set aside for these two plans. In May 2000, the Stockholders' approved
an increase in the number of shares reserved for the Incentive Plan and
Recognition Plan to a total of 7,500,000. Options granted under the
Company's plans generally vest over a period of one to five years, with
exercise prices ranging between $0.50 to $16.50. The maximum term under
these plans is 10 years.
36
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
A summary of stock option activity is as follows:
WEIGHTED
AVERAGE
NUMBER OF EXERCISE
SHARES PRICE
Outstanding at December 31, 2000 3,582,675 3.67
========= =======
Granted 537,400 0.75
Exercised (189,550) 2.02
Cancelled (95,950) 6.77
--------- -------
Outstanding at December 31, 2001 3,834,575 $ 3.72
========= =======
Granted 1,555,573 1.35
Exercised (53,000) 0.35
Cancelled (586,393) 4.04
--------- -------
Outstanding at December 31, 2002 4,750,755 $ 2.92
========= =======
Granted 1,110,350 2.80
Exercised (326,074) 0.88
Cancelled (120,414) 6.37
--------- -------
Outstanding at December 31, 2003 5,414,617 $ 2.94
========= =======
Exercisable at December 31, 2003 4,269,617 $ 2.92
========= =======
Exercisable at December 31, 2002 3,162,900 $ 3.46
========= =======
Exercisable at December 31, 2001 2,731,291 $ 3.26
========= =======
Options available for grant at December 31, 2003 1,380,259
=========
The following table summarizes information about options outstanding at
December 31, 2003:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
------------------------------------------------------ ---------------------------------
WEIGHTED AVERAGE
RANGE OF NUMBER REMAINING WEIGHTED AVERAGE NUMBER WEIGHTED AVERAGE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE EXERCISE PRICE EXERCISABLE EXERCISE PRICE
$.50 - 1.85 1,314,467 8.43 years $0.99 892,567 $0.73
2.00 - 3.85 2,209,750 5.36 years 2.45 1,808,000 2.29
4.00 - 5.50 1,754,500 6.77 years 4.19 1,433,150 4.04
7.00 - 8.00 30,000 6.45 years 8.00 30,000 8.00
12.00 - 16.25 105,900 6.81 years 15.47 105,900 15.47
--------- ----- --------- -----
5,414,617 $2.94 4,269,617 $2.92
========= ===== ========= =====
The weighted average grant date fair value of options granted during
2003, 2002 and 2001 was $2.60, $1.23 and $2.26, respectively.
The fair value of each option and warrant (note 13) is estimated on the
date of grant using the Black-Scholes option-pricing model. The following
assumptions were used in the model:
2003 2002 2001
Dividend yield 0.00% 0.00% 0.00%
Risk-free yields 1.35% - 4.58% 1.35% - 3.00% 4.39% - 6.71%
Expected volatility 100% 100% 65% - 80%
Option terms 1 - 10 years 1 - 10 years 1 - 10 years
37
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
10. COMMON STOCK
On July 2, 2003, the Company closed a private placement of its common
stock at $3.60 per share and issued a total of 2,916,669 shares and
1,020,832 four-year warrants to purchase shares of the Company's common
stock at $5.04 per share, to twelve accredited investors. One third of
the warrants are callable by the company if the market price of the
Company's common stock closes above $10.00 for seven consecutive trading
days. The Company received $10.5 million in gross proceeds.
On March 21, 2003, the Company closed a private placement of its common
stock at $1.50 per share. Pursuant to the agreement, the Company issued a
total of 210,000 shares and 157,500 three-year warrants to purchase the
Company's common stock at $2.00 per share to three accredited investors
and received $315,000 in gross proceeds.
On June 28, 2002, the Company completed a private placement of its
securities to institutional and accredited individual investors. The
Company issued a total of 2,666,670 shares of its common stock and
warrants to purchase 533,334 shares of common stock, pursuant to a Unit
Purchase Agreement. Gross proceeds from the private placement were
$6,000,000. The investors paid $11.25 per unit and received five shares
of NexMed common stock and a two-year warrant for the right to purchase
one share of common stock at $2.81.
In connection with the private placement, the Company paid a placement
agent $249,938 in cash and issued to the placement agent warrants to
purchase 222,167 shares of the Company's common stock at an exercise
price of $2.81 per share and a term of three years from the date of
issuance.
11. PREFERRED STOCK
In April 2003, the Company closed a private placement of its securities
and raised $8 million in gross proceeds. The Company sold 800 shares of
newly issued Series B convertible preferred stock at a per share price of
$10,000. The Series B preferred paid annual cumulative dividends of 8%.
The preferred shareholders had voting rights and powers identical to
those of common shareholders and could convert their preferred shares to
common stock at any time. Each preferred share was convertible into
approximately 6,375 shares of its common stock (or an aggregate of
5,100,089 shares of common stock) and included a warrant to purchase
approximately 5,499 shares of the Company's common stock at a price of
$1.43 per share.
The Company valued the warrants using the Black-Scholes pricing model and
allocated $3,037,518 of the proceeds from the preferred offering, based
upon the relative fair value of the preferred shares and the warrants, to
the warrants. Assumptions utilized in the Black-Scholes model to value
the warrants were: exercise price of $1.43 per share; fair value of the
Company's common stock on date of issuance of $1.55 per share; volatility
of 100%; term of four years and a risk-free interest rate of 2.79%.
The allocated value of the convertible preferred stock contained a
beneficial conversion feature calculated based upon the difference
between the effective conversion price of the proceeds allocated to the
convertible preferred stock, and the fair market value of the common
stock on the date of issuance. The Company recorded a deemed dividend to
the preferred shareholders of $2,942,656 representing the value of the
beneficial conversion feature of the preferred stock.
38
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
On July 1, 2003, pursuant to the Certificate of Designation of the
preferred stock, the Company issued 34,946 shares of its common stock as
payment of a dividend of $121,841. In addition a dividend of $53,347 was
declared in connection with the conversion of the preferred stock
discussed below and 35,874 shares of common stock were issued in payment
of such dividend.
The Certificate of Designation of the preferred stock provided that the
preferred stock would be automatically converted into common stock if the
twenty trading day average closing bid price of the Company's common
stock exceeded 250% of the conversion price of the preferred stock for
twenty consecutive trading days. On August 1, 2003, the foregoing
condition was satisfied and the Company issued a notice to the holders of
the preferred stock that all of the outstanding shares of preferred stock
were automatically converted into 5,100,089 shares of common stock. Thus,
as of December 31, 2003, no shares of series B preferred stock remained
outstanding.
12. STOCKHOLDER RIGHTS PLAN
On April 3, 2000, the Company declared a dividend distribution of one
preferred share purchase right (the "Right") for each outstanding share
of the Company's common stock to shareholders of record at the close of
business on April 21, 2000. One Right will also be distributed for each
share of Common Stock issued after April 21, 2000, until the Distribution
Date, described in the next paragraph. Each Right entitles the registered
holder to purchase from the Company a unit consisting of one
one-hundredths of a share (a "Unit") of Series A Junior Participating
Preferred Stock, $.001 par value per share (the "Preferred Stock"), at a
Purchase Price of $100.00 per Unit, subject to adjustment. 1,000,000
shares of the Company's preferred stock has been set-aside for the Rights
Plan.
Initially, the Rights will be attached to all Common Stock certificates
representing shares then outstanding, and no separate Rights Certificates
will be distributed. The Rights will separate from the Common Stock and a
Distribution Date will occur upon the earlier of (i) ten (10) business
days following a public announcement that a person or group of affiliated
or associated persons (an "Acquiring Person") has acquired, or obtained
the right to acquire, beneficial ownership of 15% or more of the
outstanding shares of Common Stock (the "Stock Acquisition Date"), or
(ii) ten (10) business days following the public announcement of a tender
offer or exchange offer that would, if consummated, result in a person or
group beneficially owning 15% or more of such outstanding shares of
Common Stock, subject to certain limitations.
Under the terms of the Rights Agreement, Dr. Y. Joseph Mo, who
beneficially owned approximately 12.12% of the outstanding shares of the
Company's Common Stock as of April 2000, will be permitted to continue to
own such shares and to increase such ownership to up to 25% of the
outstanding shares of Common Stock, without becoming an Acquiring Person
and triggering a Distribution Date.
13. WARRANTS
A summary of warrant activity is as follows:
39
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
WEIGHTED
COMMON SHARES AVERAGE
ISSUABLE UPON EXERCISE
EXERCISE PRICE
-------- -----
Outstanding at January 1, 2001 2,291,549 10.85
Issued 115,000 12.22
Exercised (200,000) 3.00
---------- -------
Outstanding at December 31, 2001 2,206,549 11.59
---------- -------
Issued 1,183,850 3.27
Redeemed (1,345,491) 14.31
----------
Outstanding at December 31, 2002 2,044,908 5.03
---------- -------
Issued 5,959,990 2.10
Redeemed (424,811) 3.96
Cancelled (307,826) 14.37
---------- -------
Outstanding at December 31, 2003 7,272,261 2.32
---------- -------
In connection with the preferred stock placement (Note 11), the Company
issued warrants to purchase 4,398,827 shares of common stock. Each
preferred shareholder received two-year warrants to purchase 5,499 shares
of common stock vesting in April 2005.
In connection with the private placement on June 28, 2002 (Note 9), the
Company issued warrants to purchase 533,334 shares of common stock ,
pursuant to a Unit Purchase Agreement. The investors paid $11.25 per unit
and received five shares of NexMed common stock and a two-year warrant
for the right to purchase one share of common stock at $2.81. The Company
also issued to the placement agent warrants to purchase 222,167 shares of
the Company's common stock at an exercise price of $2.81 per share and a
term of three years from the date of issuance.
In August 2001, the Company issued warrants to acquire 15,000 shares of
its common stock to a financial consultant. The warrants have an exercise
price of $7.00 per share and vested immediately. In accordance with EITF
96-18, the Company has recorded $38,550 of consulting expenses related to
these warrants, representing the fair value of these warrants using the
Black-Scholes pricing model.
In February 2001, the Company issued warrants to acquire 100,000 shares
of its common stock to a financial consultant. The warrants have an
exercise price of $13.00 per share, of which 34,000 warrants vested
immediately and the remaining warrants vested in two equal installments
on May 20, 2001 and August 20, 2001. The warrants have a three-year term.
In accordance with EITF 96-18, the Company has recorded approximately
$297,500 of consulting expense related to these warrants during 2001,
representing the fair value of these warrants using the Black-Scholes
pricing model.
40
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
14. INCOME TAXES
The Company has incurred losses since inception, which have generated net
operating loss carryforwards of approximately $47.1 million for federal
and state income tax purposes. These carryforwards are available to
offset future taxable income and expire beginning in 2011 for federal
income tax purposes. In addition, the Company has general business and
research and development tax credit carryforwards of approximately $2.7
million. Internal Revenue Code Section 382 places a limitation on the
utilization of Federal net operating loss carryforwards when an ownership
change, as defined by tax law, occurs. Generally, an ownership change, as
defined, occurs when a greater than 50 percent change in ownership takes
place during any three-year period. The actual utilization of net
operating loss carryforwards generated prior to such changes in ownership
will be limited, in any one year, to a percentage of fair market value of
the Company at the time of the ownership change. Such a change may have
already resulted from the additional equity financing obtained by the
Company since its formation.
In 2002, the Company was approved by the State of New Jersey to sell a
portion of its state tax credits pursuant to the Technology Tax
Certificate Transfer Program. The Company has approximately $1.65 million
in NJ tax credits, and was approved to sell $261,000 in 2003 and $279,000
in 2002. The Company received proceeds of $232,231 and $242,645 in 2003
and 2002, respectively, as a result of the sale of the tax credits.
The net operating loss carryforwards and tax credit carryforwards result
in a noncurrent deferred tax benefit at December 31, 2003 and 2002 of
approximately $23.1 million and $17.9 million, respectively. In
consideration of the Company's accumulated losses and the uncertainty of
its ability to utilize this deferred tax benefit in the future, the
Company has recorded a valuation allowance of an equal amount on such
date to fully offset the deferred tax benefit amount.
The reconciliation of income taxes computed using the statutory U.S.
income tax rate and the provision (benefit) for income taxes for the
years ended December 31, 2003, 2002 and 2001 are as follows:
FOR THE YEARS ENDED
DECEMBER 31,
------------
2003 2002 2001
Federal statutory tax rate (35%) (35%) (35%)
State taxes, net of federal benefit (6%) (6%) (6%)
Valuation allowance 41% 41% 41%
Sale of state net operating losses (1.33%) (0.87%) (0.00%)
------- ------- -------
PROVISION (BENEFIT) FOR INCOME TAXES (1.33%) (0.87%) (0.00%)
------- ------- -------
For the years ended December 31, 2003, 2002 and 2001, the Company's
effective tax rate differs from the federal statutory rate principally
due to net operating losses and other temporary differences for which no
benefit was recorded, state taxes and other permanent differences.
41
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Under the provisions of the Internal Revenue Code, certain substantial
changes in the Company's ownership may result in a limitation on the
amount of net operating loss carryforwards.
15. COMMITMENTS AND CONTINGENCIES
The Company is a party to clinical research agreements totaling
approximately $12.8 million. These agreements provide that upon
cancellation, the Company will owe 10% of the outstanding contract amount
at the time of cancellation. At December 31, 2003, this amounts to
$1,265,000. The Company anticipates that the clinical research in
connection with the agreements will be completed by the first half of
2005.
The Company is a party to several short-term consulting and research
agreements that, generally, can be cancelled at will by either party.
We have been the subject of a number of lawsuits. On March 22, 2003 five
former employees filed a lawsuit in the Superior Court of New Jersey
against the Company, Y. Joseph Mo, and Administaff (the co-employer who
until December 31, 2003, provided the Company's benefits), claiming their
termination was due to age discrimination and seeking unspecified
damages. This complaint is covered by a labor insurance policy the
Company maintains through Administaff and the insurance company has
appointed counsel.
Another lawsuit was filed with the Superior court of New Jersey on April
1, 2003 by one of the above five employees against the Company for an
unspecified bonus amount that he believes he should have received for
completing the construction of the Company's East Windsor facility. The
Company has engaged counsel to defend its position.
The Company intends to defend itself vigorously against the above
mentioned claims and believes it has valid defenses; however, each of the
cases are still in the preliminary stages and the likely outcomes can not
be predicted, nor can a reasonable estimate of the amount of loss, if
any, be made.
On December 29, 2003, a consultant previously engaged by the Company
filed a suit in the Superior Court of New Jersey, Chancery Division:
Mercer County, which subsequently was removed to the United States
District Court for the District of New Jersey, alleging a breach by the
Company of a consulting agreement entered into with that consultant in
January 2003. The plaintiff alleged that the Company failed to issue
certain warrants provided for under that agreement, which the Company
terminated in April 2003. The complaint did not specify any particular
amount of monetary risk and expense damages. The Company has engaged
counsel to defend its position.
The Company leases office space and research facilities under operating
lease agreements expiring through 2006. The Company also leases equipment
from GE Capital under capital leases expiring through 2006 (Note 7).
Future minimum payments under noncancellable operating and capital leases
with initial or remaining terms of one year or more, consist of the
following at December 31, 2003:
42
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
OPERATING CAPITAL
2004 $ 476,910 $ 1,017,450
2005 469,378 690,816
2006 100,823 241,099
2007 2,100 -
----------- -----------
Total minimum lease payments $ 1,049,211 $ 1,949,365
===========
Less: amount representing interest (172,627)
Present value of future minimum lease payments 1,776,738
Less: current portion (898,861)
-----------
Capital lease obligations, net of current portion $ 877,877
===========
The Company also leases office space under short-term lease agreements.
Total rent expense was $460,643, $452,052, and $535,023 in 2003, 2002,
and 2001 respectively.
On February 27, 2002, the Company entered in to an employment agreement
with Y. Joseph Mo, Ph.D., that has a constant term of five years, and
pursuant to which Dr. Mo will serve as the Company's Chief Executive
Officer and President. During his employment with the Company, Dr. Mo
will receive an annual base salary of at least $250,000 (to be raised to
$350,000 after the Company sustains gross revenues of $10 million for two
consecutive fiscal quarters), subject to annual cost of living increases.
Under the employment agreement, Dr. Mo is entitled to deferred
compensation in an annual amount equal to one sixth of the sum of Dr.
Mo's base salary and bonus for the 36 calendar months preceding the date
on which the deferred compensation payments commence subject to certain
limitations, including annual vesting through January 1, 2007, as set
forth in the employment agreement. The deferred compensation will be
payable monthly for 180 months commencing on termination of employment.
As of December 31, 2003 and 2002, the Company has accrued approximately
$458,000 and $350,000 respectively, which is included in other long-term
liabilities, based upon the estimated present value of the vested portion
of the obligation.
16. SEGMENT AND GEOGRAPHIC INFORMATION
The Company is active in one business segment: designing, developing,
manufacturing and marketing pharmaceutical products. The Company
maintains development and business development operations in the United
States and Hong Kong.
Geographic information as of December 31, 2003, 2002 and 2001 are as
follows:
43
NEXMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
FOR THE YEARS ENDED DECEMBER 31,
2003 2002 2001
---- ---- ----
NET REVENUES
United States $ 12,718 $ - $ -
Hong Kong 98,025 148,028 68,089
------------ ------------ -----------
$ 110,743 $ 148,028 $ 68,089
============ ============ ===========
DECEMBER 31,
2003 2002 2001
---- ---- ----
LONG-LIVED ASSETS
United States $ 10,583,733 $ 11,507,564 $ 7,691,517
Hong Kong - - -
------------ ------------ -----------
$ 10,583,733 $ 11,507,564 $ 7,691,517
============ ============ ===========
44
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH AUDITORS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
In accordance with Exchange Act Rules 13a-15 and 15d-15, the Company's
management carried out an evaluation with participation of the Company's Chief
Executive Officer and Chief Financial Officer, its principal executive officer
and principal financial officer, respectively, of the effectiveness of the
Company's disclosure controls and procedures as of the end of the period covered
by this report. Based upon that evaluation, the Chief Executive Officer and
Chief Financial Officer concluded as of the end of the period covered by this
Form 10-K that the Company's disclosure controls and procedures are effective in
timely alerting them to material information relating to the Company (including
the Company's consolidated subsidiaries) required to be included in periodic
reports filed under the Securities Exchange Act of 1934, as amended. There were
no changes in the Company's internal controls over financial reporting
identified in connection with the evaluation by the Chief Executive Officer and
Acting Chief Financial Officer that occurred during the Company's fourth quarter
that have materially affected or are reasonably likely to materially affect the
Company's internal controls over financial reporting.
PART III.
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
Information called for by Item 10 is set forth under the heading
"Election of Directors" and "Committees of the Board" in the 2004 Proxy
Statement, which is incorporated herein by this reference and "Executive
Officers" of Part I of this Report.
We have not yet adopted a code of ethics for our principal executive
officer and principal financial officer due to time constraints in light of
the recent imposition of the disclosure requirement. However, we intend to adopt
such a code of ethics at our next board meeting on May 24, 2004. At such time,
we will post the text of our code of ethics on our
45
Internet website at www.nexmed.com. In addition, we will disclose on
our website the nature of any amendments to, or waivers from, our code
of ethics in accordance with all applicable laws and regulations.
ITEM 11. EXECUTIVE COMPENSATION.
Information called for by Item 11 is set forth under the heading
"Executive Compensation" in the 2004 Proxy Statement, which is incorporated
herein by this reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.
Other than as set forth below, information called for by Item 12 is set
forth under the heading "Security Ownership of Certain Beneficial Owners and
Management" in the 2004 Proxy Statement, which is incorporated herein by this
reference.
EQUITY COMPENSATION PLAN INFORMATION
The following table gives information as of December 31, 2003, about
NexMed Stock that may be issued upon the exercise of options, warrants and
rights under all of our existing equity compensation plans (together, the
"Equity Plans"):
(a) (b) (c)
- --------------------- ------------------------ ----------------------- ------------------------------------------
Number of securities
to be issued upon Weighted-average Number of securities remaining available
Plan category exercise of exercise price of for future issuance under equity
outstanding options, outstanding options, compensation plans (excluding securities
warrants and rights warrants and rights reflected in column (a))
- --------------------- ------------------------ ----------------------- ------------------------------------------
Equity compensation
plans approved by 5,414,617 (1) $2.94 1,380,259 (2)
security holders
- --------------------- ------------------------ ----------------------- ------------------------------------------
Equity compensation
plans not approved by - - -
security holders
- --------------------- ------------------------ ----------------------- ------------------------------------------
Total 5,414,617 $2.94 1,380,259
- --------------------- ------------------------ ----------------------- ------------------------------------------
(1) Consists of options outstanding at December 31, 2003 under The NexMed Inc.
Stock Option and Long Term Incentive Plan (the "Incentive Plan") and The NexMed
Inc. Recognition and Retention Stock Incentive Plan (the "Recognition Plan").
(2) Consists of the aggregate number of shares of Stock that remain available
for future issuance, at December 31, 2003, under all of our stockholder approved
Equity Plans. This consists of 1,014,859 shares available under the Incentive
Plan and 365,400 shares available under the Recognition Plan.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
Information called for by Item 13 is set forth under the heading
"Certain Relationships and Related Transactions" in the 2004 Proxy Statement,
which is incorporated herein by this reference.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.
Information called for by item 14 is set forth under the heading
"Principal Accountant Fees and Services" in the 2004 Proxy Statement, which is
incorporated herein by reference.
PART IV.
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.
(a) 1. Financial Statements:
The information required by this item is included in Item 8 of
Part II of this Form 10-K.
2. Financial Statement Schedules
Report of Independent Accountants on Financial Statement
Schedule for the three years in the period ended December 31,
2003.
Schedule II - Valuation and Qualifying Accounts.
REPORT OF INDEPENDENT AUDITORS ON FINANCIAL STATEMENT SCHEDULE
To the Board of Directors and Stockholders of NexMed, Inc.
Our audits of the consolidated financial statements referred to in our report
dated February 27, 2004 appearing in the Annual Report to Shareholders of
NexMed, Inc. (which report and consolidated financial statements are included in
this Annual Report on Form 10-K), also included an audit of the financial
statement schedule listed in Item 15(a)(2) of this Form 10-K. In our opinion,
this financial statement schedule, presents fairly, in all material respects,
the information set forth therein when read in conjunction with the related
consolidated financial statements.
/s/ PricewaterhouseCoopers LLP
- ------------------------------
PricewaterhouseCoopers LLP
New York, New York
February 27, 2004
SCHEDULE II
-----------
NEXMED, INC.
------------
SCHEDULE OF VALUATION AND QUALIFYING ACCOUNTS
---------------------------------------------
Balance at Charged to Charged to
Beginning Costs and Other Balance at
Description of Year Expenses Accounts Deductions End of Year
----------- ------- -------- -------- ---------- -----------
YEAR ENDED DECEMBER 31, 2003
Valuation allowance - deferred tax asset $17,901,534 $5,196,543 -- -- $23,098,077
YEAR ENDED DECEMBER 31, 2002
Valuation allowance - deferred tax asset $8,699,708 $9,201,826 -- -- $17,901,534
YEAR ENDED DECEMBER 31, 2001
Valuation allowance - deferred tax asset $4,572,023 $4,127,685 -- -- $8,699,708
All other schedules have been omitted because the information
is not applicable or is presented in the Financial Statements
or Notes thereto.
3. Exhibits
--------
EXHIBITS DESCRIPTION
NO.
---
3.1 Amended and Restated Articles of Incorporation of the Company (incorporated by reference to
Exhibit 2.1 filed with the Company's Form 10-SB filed with the Securities and Exchange Commission
on March 14, 1997).
3.2 Amended and Restated By-laws of the Company (incorporated herein by reference to Exhibit 3.1 to the
Company's Form 10-Q filed with the Securities and Exchange Commission on May 14, 2003).
3.3 Certificate of Amendment to Articles of Incorporation of the Company, dated June 22, 2000
(incorporated herein by reference to Exhibit 3.2 to the Company's Form 10-K filed with the
Securities and Exchange Commission on March 31, 2003).
47
4.1 Form of Common Stock Certificate (incorporated by reference to Exhibit 3.1 filed with the
Company's Form 10-SB filed with the Securities and Exchange Commission on March 14, 1997).
4.2 Rights Agreement and form of Rights Certificate (incorporated herein by reference to Exhibit 4 to
our Current Report on Form 8-K filed with the Commission on April 10, 2000).
4.3 Certificate of Designation of Series A Junior Participating Preferred Stock (incorporated herein
by reference to Exhibit 4 to our Current Report on Form 8-K filed with the Commission on April
10, 2000).
4.4 Certificate of Designation of the Company's Series B 8% Cumulative Convertible Preferred Stock
(incorporated herein by reference to Exhibit 4.1 to the Company's Form 10-Q filed with the
Securities and Exchange Commission on May 14, 2003).
4.5 Form of Warrant dated April 21, 2003 (incorporated herein by reference to Exhibit 4.2 to the
Company's Form 10-Q filed with the Securities and Exchange Commission on May 14, 2003).
4.6 Form of Common Stock Purchase Warrant dated July 2, 2003 (incorporated herein by reference to
Exhibit 4.3 to the Company's Registration Statement on Form S-3 filed with the Securities and
Exchange Commission on July 17, 2003).
10.1* Amended and Restated NexMed, Inc. Stock Option and Long-Term Incentive Compensation Plan
(incorporated by reference to Exhibit 10.1 filed with the Company's Form 10-Q filed with the
Securities and Exchange Commission on May 15, 2001).
10.2* The NexMed, Inc. Recognition and Retention Stock Incentive Plan incorporated by reference to
Exhibit 6.5 filed with the Company's Form 10-SB/A filed with the Securities and Exchange
Commission on June 5, 1997).
10.3* Form of Agreement dated November 15, 1995 between NexMed, Inc. and each of Y. Joseph Mo, Ph.D.,
Vivian H. Liu and Gilbert S. Banker, Ph.D, which are collectively commonly referred to by NexMed,
Inc. as the Non-Qualified Performance Incentive Program (filed as Exhibit 4.2 to our Registration
Statement on Form 8-A filed with the Securities and Exchange Commission on December 22, 1999,
including any amendment or report filed for the purpose of updating such information, and
incorporated herein by reference).
10.4 License Agreement dated March 22, 1999 between NexMed International Limited and Vergemont
International Limited (incorporated by reference to Exhibit 10.7 of the Company's Form 10-KSB
filed with the Securities and Exchange Commission on March 16, 2000).
10.5* The NexMed, Inc. Non-Qualified Stock Option Plan (incorporated by reference to Exhibit 6.6 filed
with the Company's Form 10-SB/A filed with the Securities and Exchange Commission on June 5,
1997).
10.6 Form of Unit Purchase Agreement between the Company and each investor who purchased units relating
the Company's private placement dated August and July 2000 (incorporated by reference to Exhibit
4.2 filed with the Company's Form S-3 filed with the Securities and Exchange Commission on
September 29, 2000).
10.7* Employment Agreement dated February 26, 2002 by and between NexMed, Inc. and Dr. Y. Joseph Mo
(incorporated by reference to Exhibit 10.7 of the Company's Form 10-K filed with the Securities and
Exchange Commission on March 29, 2002 ).
10.8 Letter Agreement dated February 6, 2001, by and among NexMed, Inc. and General Electric Capital
Corporation (Incorporated by reference to Exhibit 10.8 of the Company's Form 10-K filed with the
Securities and Exchange Commission on March 29, 2002.)
10.9 Letter Agreement dated January 2, 2002, by and among NexMed, Inc. and General Electric Capital
Corporation (Incorporated by reference to Exhibit 10.8 of the Company's Form 10-K filed with the
Securities and Exchange Commission on March 29, 2002.)
48
10.10 Purchase Agreement between the Company and The Tailwind Fund Ltd. and Solomon Strategic Holdings,
Inc. dated June 11, 2002 (incorporated herein by reference to Exhibit 10.1 to the Company's Form
10-Q filed with the Securities and Exchange Commission on August 14, 2002).
10.11 Registration Rights Agreement between the Company and The Tailwind Fund Ltd. and Solomon
Strategic Holdings, Inc. dated June 11, 2002 (incorporated herein by reference to Exhibit 10.2 to
the Company's Form 10-Q filed with the Securities and
Exchange Commission on August 14, 2002).
10.12 Subsidiary Guaranty by NexMed (U.S.A.), Inc., a wholly owned subsidiary of the Company, in favor
of The Tailwind Fund Ltd. and Solomon Strategic Holdings, Inc. dated June 11, 2002 (incorporated
herein by reference to Exhibit 10.3 to the Company's Form 10-Q filed with the Securities and
Exchange Commission on August 14, 2002).
10.13 Mortgage, Security Agreement and Assignment of Leases and Rents by NexMed (U.S.A.), Inc., a
wholly owned subsidiary of the Company, in favor of The Tailwind Fund Ltd. and Solomon Strategic
Holdings, Inc. dated June 11, 2002 (incorporated herein by reference to Exhibit 10.4 to the
Company's Form 10-Q filed with the Securities and Exchange Commission on August 14, 2002).
10.14 Form of Unit Purchase Agreement dated June 28, 2002 (incorporated herein by reference to Exhibit
10.5 to the Company's Form 10-Q filed with the Securities and Exchange Commission on August 14,
2002).
10.15 Preferred Stock and Warrant Purchase Agreement, dated as of April 21, 2003, between the Company
and the Purchasers identified on Schedule 1 to the Purchase Agreement (incorporated herein by
reference to Exhibit 10.1 to the Company's Form 10-Q filed with the Securities and Exchange
Commission on May 14, 2003).
10.16 Investor Rights Agreement, dated as of April 21, 2003, between the Company and the Purchasers
identified on Schedule 1 to the Investor Rights Agreement (incorporated herein by reference to
Exhibit 10.2 to the Company's Form 10-Q filed with the Securities and Exchange Commission on May
14, 2003).
10.17 Common Stock and Warrant Purchase Agreement, dated as of July 2, 2003, between the Company and
the Purchasers identified on Schedule 1 to the Purchase Agreement (incorporated herein by reference
to Exhibit 10.1 to the Company's Registration Statement on Form S-3 filed with the Securities and
Exchange Commission on July 17, 2003).
10.18 Investor Rights Agreement, dated as of July 2, 2003, between the Company and the Purchasers identified
on Schedule 1 to the Investor Rights Agreement (incorporated herein by reference to Exhibit 10.2 to
the Company's Registration Statement on Form S-3 filed with the Securities and Exchange Commission
on July 17, 2003).
10.19 Letter Agreement dated July 12, 2003, between NexMed, Inc. and General Electric Capital
Corporation (incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q filed
with the Securities and Exchange Commission on August 12, 2003).
10.20* Employment Agreement dated September 26, 2003 by and between NexMed, Inc. and James L. Yeager
(incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q filed with the
Securities and Exchange Commission on November 12, 2003).
10.21* Employment Agreement dated September 26, 2003 by and between NexMed, Inc. and Kenneth F. Anderson
(incorporated herein by reference to Exhibit 10.2 to the Company's Form 10-Q filed with the
Securities and Exchange Commission on November 12, 2003)..
10.22* Employment Agreement dated September 26, 2003 by and between NexMed, Inc. and Vivian H. Liu
(incorporated herein by reference to Exhibit 10.3 to the Company's Form 10-Q filed with the
Securities and Exchange Commission on November 12, 2003).
49
10.23* Amendment dated September 26, 2003 to Employment Agreement by and between Dr. Y. Joseph Mo and
NexMed, Inc. dated February 26, 2002 (incorporated herein by reference to Exhibit 10.4 to the
Company's Form 10-Q filed with the Securities and Exchange Commission on November 12, 2003).
10.24 Purchase Agreement, dated as of December 12, 2003, between the Company and the Purchasers named
therein (incorporated herein by reference to Exhibit 10.1 to the Company's Registration
Statement on Form S-3 filed with the Securities and Exchange Commission on January 13, 2004).
10.25 Registration Rights Agreement, dated as of December 12, 2003, between the Company and the
Purchasers named therein (incorporated herein by reference to Exhibit 10.2 to the Company's
Registration Statement on Form S-3 filed with the Securities and Exchange Commission on January
13, 2004).
10.26 Form of 5% Convertible Note due May 31, 2007 (incorporated herein by reference to Exhibit 10.3 to
the Company's Registration Statement on Form S-3 filed with the Securities and Exchange
Commission on January 13, 2004).
10.27 First Amendment of Mortgage, Security Agreement and Assignment of Leases and Rents by NexMed
(U.S.A.), Inc., in favor of The Tail Wind Fund Ltd. and Solomon Strategic Holdings, Inc., dated
as of December 12, 2003 (incorporated herein by reference to Exhibit 10.4 to the Company's
Registration Statement on Form S-3 filed with the Securities and Exchange Commission on January
13, 2004).
10.28 Subsidiary Guaranty by NexMed (U.S.A.), Inc., a wholly owned subsidiary of the Company, in favor
of The Tailwind Fund Ltd. and Solomon Strategic Holdings, Inc. dated December 12, 2003.
21 Subsidiaries.
23 Consent of PricewaterhouseCoopers LLP, independent accountants.
31.1 Chief Executive Officer's Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Chief Financial Officer's Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Chief Executive Officer's Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Chief Financial Officer's Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
*Management compensatory plan or arrangement required to be filed as an
exhibit pursuant to Item 15(c) of Form 10-K.
(b) Reports on Form 8-K
-------------------
There were no reports on Form 8-K filed by the Company during the
fourth quarter of 2003.
50
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
NEXMED, INC.
Dated: March 4, 2004 By: /s/ Y. Joseph Mo
---------------------------------------------
Y. Joseph Mo
Chairman of the Board of Directors, President
and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
SIGNATURE TITLE DATE
--------- -----
/s/ Y. Joseph Mo Chairman of the Board of Directors, President and March 4, 2004
- ------------------------- Chief Executive Officer
Y. JOSEPH MO
/s/ Vivian H. Liu
- -------------------------
VIVIAN H. LIU Vice President, Chief Financial Officer and Secretary March 4, 2004
/s/ James Yeager
- -------------------------
JAMES YEAGER Director, Senior Vice-President, Scientific Affairs March 4, 2004
/s/ Richard J. Berman
- -------------------------
RICHARD J. BERMAN Director March 4, 2004
/s/ Arthur D. Emil
- -------------------------
ARTHUR D. EMIL Director March 4, 2004
/s/ Robert W. Gracy
- -------------------------
ROBERT W. GRACY Director March 4, 2004
/s/ Stephen M. Sammut
- -------------------------
STEPHEN M. SAMMUT Director March 4, 2004
/s/ Martin Wade III
- -------------------------
MARTIN WADE III Director March 4, 2004
51
EXHIBIT INDEX
EXHIBITS DESCRIPTION
NO.
---
10.28 Subsidiary Guaranty by NexMed (U.S.A.), Inc., a wholly owned subsidiary of the Company, in favor
of The Tailwind Fund Ltd. and Solomon Strategic Holdings, Inc. dated December 12, 2003.
21 Subsidiaries.
23 Consent of PricewaterhouseCoopers LLP, independent accountants.
31.1 Chief Executive Officer's Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Chief Financial Officer's Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Chief Executive Officer's Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Chief Financial Officer's Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
52